<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="mco270500" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jats-oasis2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MedComm (2020)</journal-id><journal-id journal-id-type="iso-abbrev">MedComm (2020)</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2688-2663</journal-id><journal-id journal-id-type="publisher-id">MCO2</journal-id><journal-title-group><journal-title>MedComm</journal-title></journal-title-group><issn pub-type="epub">2688-2663</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12627232</article-id><article-id pub-id-type="doi">10.1002/mco2.70500</article-id><article-id pub-id-type="publisher-id">MCO270500</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Preclinical Characterization of SDFZ&#x02010;8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy</article-title></title-group><contrib-group><contrib id="mco270500-cr-0001" contrib-type="author"><name><surname>Zhou</surname><given-names>Yi</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mco270500-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270500-cr-0002" contrib-type="author"><name><surname>Du</surname><given-names>Jintong</given-names></name><xref rid="mco270500-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mco270500-cr-0003" contrib-type="author"><name><surname>Li</surname><given-names>Xue</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270500-cr-0004" contrib-type="author"><name><surname>Zhao</surname><given-names>Huajun</given-names></name><xref rid="mco270500-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="mco270500-cr-0005" contrib-type="author"><name><surname>Xue</surname><given-names>Junxin</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270500-cr-0006" contrib-type="author"><name><surname>Liu</surname><given-names>Yuchen</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270500-cr-0007" contrib-type="author"><name><surname>Yang</surname><given-names>Xinying</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270500-cr-0008" contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Jinming</given-names></name><xref rid="mco270500-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>sdyujinming@163.com</email></address></contrib><contrib id="mco270500-cr-0009" contrib-type="author" corresp="yes"><name><surname>Hou</surname><given-names>Xuben</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>hxb@sdu.edu.cn</email></address></contrib><contrib id="mco270500-cr-0010" contrib-type="author" corresp="yes"><name><surname>Fang</surname><given-names>Hao</given-names></name><xref rid="mco270500-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>haofangcn@sdu.edu.cn</email></address></contrib></contrib-group><aff id="mco270500-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medicinal Chemistry</named-content>
<named-content content-type="organisation-division">State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine</named-content>
<named-content content-type="organisation-division">Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds</named-content>
<institution>School of Pharmaceutical Science, Cheeloo College of Medicine, Shandong University</institution>
<city>Ji'nan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><aff id="mco270500-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacy</named-content>
<institution>Shandong Provincial Hospital Affiliated to Shandong First Medical University</institution>
<city>Ji'nan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><aff id="mco270500-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Shandong Cancer Hospital and Institute</institution>
<institution>Shandong First Medical University</institution>
<city>Ji'nan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><aff id="mco270500-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Immunopharmaceutical Sciences</named-content>
<named-content content-type="organisation-division">School of Pharmaceutical Science</named-content>
<institution>Cheeloo College of Medicine, Shandong University</institution>
<city>Ji'nan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><pub-date pub-type="epub"><day>18</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>6</volume><issue seq="90">12</issue><issue-id pub-id-type="doi">10.1002/mco2.v6.12</issue-id><elocation-id>e70500</elocation-id><history>
<date date-type="rev-recd"><day>11</day><month>9</month><year>2025</year></date>
<date date-type="received"><day>25</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>30</day><month>9</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">MedComm</italic> published by Sichuan International Medical Exchange &#x00026; Promotion Association (SCIMEA) and John Wiley &#x00026; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:MCO2-6-e70500.pdf"/><abstract><title>ABSTRACT</title><p>The histone deacetylases (HDACs) family plays a critical role in tumorigenesis and has been identified as having a significant impact on tumor immunity. Herein, we employed a fragment&#x02010;centric structure&#x02010;based design platform, leading to the discovery of <bold>SDFZ&#x02010;8</bold> as a highly potent HDAC1 inhibitor (IC<sub>50</sub>&#x000a0;=&#x000a0;0.4&#x000a0;nM). <bold>SDFZ&#x02010;8</bold> exhibits strong antiproliferative effects by enabling histone acetylation and inducing cell apoptosis. Crucially, <bold>SDFZ&#x02010;8</bold> treatment led to a significant enhancement of antitumor immunity, as evidenced by&#x000a0;increased activation of T cells, enhanced polarization of M1&#x02010;type macrophages, improved antigen presentation, and alleviation of the immunosuppressive tumor microenvironment. Specifically, we observed that <bold>SDFZ&#x02010;8</bold> notably upregulated the expression of PD&#x02010;L1 in both tumor cells and tumor&#x02010;infiltrating lymphocytes, which is closely associated with its inhibition against HDAC1. Of particular interest, combining <bold>SDFZ&#x02010;8</bold> with PD&#x02010;L1 blockade resulted in a synergistic antitumor effect surpassing that of either monotherapy. Taken together, our findings establish <bold>SDFZ&#x02010;8</bold> as a novel HDAC1 inhibitor&#x000a0;that concurrently targets tumor cells and immune evasion mechanisms, providing a rational combinatorial strategy to enhance cancer immunotherapy efficacy.</p></abstract><abstract id="mco270500-abs-0001" abstract-type="graphical"><p>In this study, we designed a novel quinoline derivative as a potent HDAC inhibitor <bold>SDFZ&#x02010;8</bold> and assessed its capability to enhance cancer immunotherapy, along with its potential synergistic effects with PD&#x02010;L1 blockade.
<boxed-text position="anchor" content-type="graphic"><graphic xlink:href="MCO2-6-e70500-g003.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mco270500-kwd-0001">cancer immunotherapy</kwd><kwd id="mco270500-kwd-0002">HDAC inhibitor</kwd><kwd id="mco270500-kwd-0003">PD&#x02010;L1 blockade</kwd><kwd id="mco270500-kwd-0004">structure&#x02010;based drug design</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>
<institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap>
</funding-source><award-id>81874288</award-id><award-id>82003590</award-id><award-id>22377068</award-id><award-id>82204198</award-id><award-id>92053105</award-id></award-group><award-group id="funding-0002"><funding-source>
<institution-wrap><institution>the Taishan Scholars Program of Shandong Province</institution></institution-wrap>
</funding-source><award-id>tstp20230606</award-id></award-group><award-group id="funding-0003"><funding-source>
<institution-wrap><institution>the Shandong Provincial Youth Innovation Team Development Program</institution></institution-wrap>
</funding-source><award-id>2023KJ026</award-id></award-group><award-group id="funding-0004"><funding-source>
<institution-wrap><institution>Advanced Medical Research Institute, Shandong University</institution></institution-wrap>
</funding-source></award-group></funding-group><counts><fig-count count="8"/><table-count count="2"/><page-count count="16"/><word-count count="9122"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:19.11.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="mco270500-cit-0001">
<string-name>
<given-names>Y.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Du</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, et al. &#x0201c;<article-title>Preclinical Characterization of SDFZ&#x02010;8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy</article-title>.&#x0201d; <source>MedComm</source>
<volume>6</volume>, no. <issue>12</issue> (<year>2025</year>): <elocation-id>e70500</elocation-id>. <pub-id pub-id-type="doi">10.1002/mco2.70500</pub-id>
</mixed-citation>
</p><fn-group><fn id="mco270500-note-0001" fn-type="equal"><p>Yi Zhou, Jintong Du, and Xue Li contributed equally to this work.</p></fn></fn-group></notes></front><body><sec id="mco270500-sec-0010"><label>1</label><title>Introduction</title><p>Histone acetylation is one of the most studied epigenetic modifications and plays a critical role in the modification of the chromatin structure [<xref rid="mco270500-bib-0001" ref-type="bibr">1</xref>]. Typically, the acetylation status of histones is mainly regulated by two groups of enzymes, histone deacetylases (HDACs) and histone acetyltransferases [<xref rid="mco270500-bib-0002" ref-type="bibr">2</xref>]. HDACs catalyzed the removal of the acetyl group from the lysine of histone and nonhistone proteins, controlling the elasticity of histone and DNA or other cell signal transduction, thereby stimulating the gene expressions [<xref rid="mco270500-bib-0003" ref-type="bibr">3</xref>, <xref rid="mco270500-bib-0004" ref-type="bibr">4</xref>, <xref rid="mco270500-bib-0005" ref-type="bibr">5</xref>]. Based on the dependency of specific cofactors, 18 human HDACs can be divided into two families: the zinc&#x02010;dependent HDAC (HDAC1&#x02013;11) and the NAD<sup>+</sup>&#x02010;dependent sirtuin family (SIRT1&#x02013;7) [<xref rid="mco270500-bib-0006" ref-type="bibr">6</xref>]. Zinc&#x02010;dependent HDACs can be subdivided into four classes (class I&#x02013;IV) based on sequence similarity to yeast deacetylases, among which class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) are well studied and proved to be closely related to the development of cancer [<xref rid="mco270500-bib-0007" ref-type="bibr">7</xref>, <xref rid="mco270500-bib-0008" ref-type="bibr">8</xref>].</p><p>Class I HDACs drive tumor progression through dual mechanisms. First, they directly regulate oncogenic pathways by deacetylating transcription factors (e.g., p53, STAT3) and chromatin modifiers [<xref rid="mco270500-bib-0009" ref-type="bibr">9</xref>, <xref rid="mco270500-bib-0010" ref-type="bibr">10</xref>, <xref rid="mco270500-bib-0011" ref-type="bibr">11</xref>, <xref rid="mco270500-bib-0012" ref-type="bibr">12</xref>, <xref rid="mco270500-bib-0013" ref-type="bibr">13</xref>, <xref rid="mco270500-bib-0014" ref-type="bibr">14</xref>]. Second, emerging evidence reveals their critical role in shaping the tumor microenvironment (TME)&#x02014;HDAC1/2 suppress antigen presentation machinery in cancer cells, while HDAC3 promotes immunosuppressive macrophage polarization. These findings position class I HDACs as dual therapeutic targets for simultaneously attacking cancer cells and reversing immune evasion [<xref rid="mco270500-bib-0015" ref-type="bibr">15</xref>, <xref rid="mco270500-bib-0016" ref-type="bibr">16</xref>, <xref rid="mco270500-bib-0017" ref-type="bibr">17</xref>, <xref rid="mco270500-bib-0018" ref-type="bibr">18</xref>, <xref rid="mco270500-bib-0019" ref-type="bibr">19</xref>, <xref rid="mco270500-bib-0020" ref-type="bibr">20</xref>].</p><p>The development of HDAC inhibitors has evolved significantly since the approval of first&#x02010;generation pan&#x02010;inhibitors like <bold>Vorinostat</bold> (<bold>SAHA</bold>) and <bold>Romidepsin</bold> for T&#x02010;cell lymphomas. While these broad&#x02010;spectrum agents demonstrated clinical efficacy, their dose&#x02010;limiting toxicities stemming from nonselective HDAC inhibition spurred the pursuit of isoform&#x02010;selective compounds [<xref rid="mco270500-bib-0021" ref-type="bibr">21</xref>]. Recent advances have yielded class I&#x02010;selective inhibitors such as <bold>Chidamide</bold> (approved in China for peripheral T&#x02010;cell lymphoma) and <bold>Mocetinostat</bold> (HDAC1/2/3/11 selective inhibitor). However, challenges persist in balancing selectivity, potency, and pharmacokinetic properties, particularly for solid tumors where poor vascularization limits drug accumulation [<xref rid="mco270500-bib-0022" ref-type="bibr">22</xref>]. Heretofore, none of existing HDAC inhibitor has demonstrated clinically meaningful synergy with immune checkpoint blockers, likely due to incomplete understanding of HDAC&#x02013;immune crosstalk [<xref rid="mco270500-bib-0023" ref-type="bibr">23</xref>].</p><p>To address these limitations, we hypothesized that a&#x000a0;class I&#x02010;selective HDAC1 inhibitor&#x000a0;with optimized pharmacokinetics could achieve dual tumor&#x02010;intrinsic and immune&#x02010;modulatory effects. Our strategy leveraged the <italic toggle="yes">AlphaSpace</italic> platform&#x02014;a fragment&#x02010;centric computational tool that maps druggable subpockets in HDAC1's catalytic domain. Through iterative structure&#x02010;based design, we developed <bold>SDFZ&#x02010;8</bold>, a quinoline derivative engineered for enhanced isoform selectivity and TME penetration.</p><p>In this study, we report the novel HDAC1 inhibitor, <bold>SDFZ&#x02010;8</bold>, developed through structure&#x02010;based design using our fragment&#x02010;centric <italic toggle="yes">AlphaSpace</italic> platform [<xref rid="mco270500-bib-0024" ref-type="bibr">24</xref>]. Unlike existing pan&#x02010;HDAC inhibitors (e.g., <bold>SAHA</bold>), <bold>SDFZ&#x02010;8</bold> achieves&#x000a0;subnanomolar HDAC1 potency (IC<sub>50</sub>&#x000a0;=&#x000a0;0.4&#x000a0;nM, 92&#x02010;fold superior to <bold>SAHA</bold>)&#x000a0;while maintaining class I selectivity, addressing a critical limitation of current therapies that suffer from off&#x02010;target toxicity. Beyond direct tumor suppression, our work&#x000a0;uncovers a novel dual mechanism: <bold>SDFZ&#x02010;8</bold> not only inhibits HDAC1&#x02010;driven oncogenesis but also reprograms the tumor immune microenvironment by activating T cells, enhancing antigen presentation, and reversing macrophage&#x02010;mediated immunosuppression. Importantly, we establish a previously unrecognized link between HDAC1 inhibition and PD&#x02010;L1 upregulation, providing a rational basis for combining <bold>SDFZ&#x02010;8</bold> with PD&#x02010;L1 blockade. This study bridges a key gap in HDAC&#x02010;targeted therapy by demonstrating that&#x000a0;precision HDAC1 inhibition can simultaneously target cancer cells and overcome immune evasion, offering a transformative paradigm for small&#x02010;molecule cancer immunotherapy.</p></sec><sec id="mco270500-sec-0020"><label>2</label><title>Results</title><sec id="mco270500-sec-0030"><label>2.1</label><title>Rational Design of Quinoline Derivatives for HDAC Inhibition</title><p>Quinoline is widely utilized in drug design and has been considered as a privileged scaffold in drug development [<xref rid="mco270500-bib-0025" ref-type="bibr">25</xref>]. Our previous research efforts have yielded a variety of quinoline derivatives as HDAC inhibitors (e.g., <bold>CC&#x02010;4a</bold> and <bold>WL&#x02010;9w</bold>). However, there is still a need to enhance their potency and selectivity [<xref rid="mco270500-bib-0026" ref-type="bibr">26</xref>, <xref rid="mco270500-bib-0027" ref-type="bibr">27</xref>]. A major challenge in developing selective HDAC inhibitors lies in the high degree of structural conservation among different HDAC subtypes. To address this challenge, we utilized <italic toggle="yes">AlphaSpace</italic> [<xref rid="mco270500-bib-0028" ref-type="bibr">28</xref>] to detect the binding pockets of our lead compounds in HDAC1 and identified unoccupied pocket the protein surfaces surrounding the 4&#x02010;position of quinoline group (Figure&#x000a0;<xref rid="mco270500-fig-0001" ref-type="fig">1A</xref>). Based on these findings, we undertook structural optimization of lead compounds by introducing various substitutions at the 4&#x02010;position of quinoline and by directly attaching the amide linkage to the quinoline (Figure&#x000a0;<xref rid="mco270500-fig-0001" ref-type="fig">1B</xref>). The HDAC inhibitory activities of all target compounds were initially assessed using HeLa nuclear extract, which mainly consist class I HDACs. The known HDAC inhibitors <bold>SAHA</bold> and <bold>LBH&#x02010;589</bold> were used as positive controls for comparison (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S1</xref>). As indicated in Figure&#x000a0;<xref rid="mco270500-fig-0001" ref-type="fig">1B</xref>, the long&#x02010;chain hydroxamic acids exhibited superior HDAC inhibitory activity. Specifically, hydroxamic acids with a chain length of 6 carbons demonstrated higher activity compared with those with a chain length of 5 carbons (<bold>SDFZ&#x02010;8&#x000a0;</bold>vs. <bold>SDFZ&#x02010;2</bold>). Additionally, for the R group, benzyl was found to be more favorable than substituted phenyl or other groups (<bold>SDFZ&#x02010;8</bold>&#x000a0;vs. <bold>SDFZ&#x02010;5</bold>, <bold>SDFZ&#x02010;6</bold>, and <bold>SDFZ&#x02010;7</bold>). The target compound <bold>SDFZ&#x02010;8</bold> exhibits&#x000a0;nanomolar HDAC inhibitory activity (IC<sub>50</sub>&#x000a0;=&#x000a0;10&#x000a0;nM), surpassing the positive control drugs <bold>SAHA</bold> by 28.6&#x02010;fold and <bold>LBH&#x02010;589</bold> by 2.5&#x02010;fold (Figure&#x000a0;<xref rid="mco270500-fig-0001" ref-type="fig">1C</xref>).&#x000a0;However, for <italic toggle="yes">N</italic>&#x02010;hydroxycinnamamide target compounds, both meta&#x02010; and para&#x02010;substituted cinnamamide derivatives generally displayed poor activity (<bold>SDFZ&#x02010;9</bold>&#x02013;<bold>SDFZ&#x02010;21</bold>), suggesting that <italic toggle="yes">N</italic>&#x02010;hydroxycinnamamide derivatives may not align with our design objectives.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0001"><label>FIGURE 1</label><caption><p>Rational design and in vitro HDAC inhibitory profiling of <bold>SDFZ&#x02010;8</bold>. (A) Structure&#x02010;based design of new HDAC inhibitors using fragment&#x02010;centric topographic mapping strategy. The favorable binding mode of <bold>SDFZ&#x02010;8</bold> was predicted using Glide. The lead compounds <bold>WL&#x02010;9w</bold> and <bold>CC&#x02010;4a</bold> were presented as tan and gray molecules in the active site of HDAC1 (PDB: 5ICN). The transparent spheres represent pockets that are detected by <italic toggle="yes">AlphaSpace</italic>. The alpha&#x02010;atoms clusters in each pocket were presented as small spheres with different colors. The unoccupied pockets were marked with a red cycle. The images were illustrated by UCSF Chimera. (B) The chemical structure and HDAC inhibitory activities of the quinoline derivatives were determined by HeLa extract. Results are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SD of three separate determinations. (C) The HDAC inhibition curve of selected compounds at different concentrations of three separate determinations. (D) Western blotting analysis of MDA&#x02010;MB&#x02010;231 cells incubated with selected compounds (&#x000b5;M) for 24&#x000a0;h. (E) Immunofluorescence of ac&#x02010;H3 in MDA&#x02010;MB&#x02010;231 cells incubated with 1 &#x000b5;M selected compounds for 24&#x000a0;h.</p></caption><graphic xlink:href="MCO2-6-e70500-g004" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="mco270500-sec-0040"><label>2.2</label><title>HDAC Isoform Selectivity of SDFZ&#x02010;8</title><p>Since <bold>SDFZ&#x02010;8</bold> emerges as a potent class I HDAC inhibitor, we further assessed its isoform selectivity against different HDACs (Table&#x000a0;<xref rid="mco270500-tbl-0001" ref-type="table">1</xref>). Specifically, among class I HDACs, <bold>SDFZ&#x02010;8</bold> demonstrated high potent inhibition of HDAC1 (IC<sub>50</sub>&#x000a0;=&#x000a0;0.4&#x000a0;nM) and HDAC2 (IC<sub>50</sub>&#x000a0;=&#x000a0;5.8&#x000a0;nM), along with more than 800&#x02010;fold selectivity toward HDAC3 and HDAC8 (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S2</xref>). Within class IIb HDACs, <bold>SDFZ&#x02010;8</bold> displayed potent inhibition against HDAC6 (IC<sub>50</sub>&#x000a0;=&#x000a0;3.1&#x000a0;nM) and demonstrated high selectivity toward HDAC10 (IC<sub>50</sub>&#x000a0;&#x0003e;&#x000a0;10,000&#x000a0;nM). Additionally, <bold>SDFZ&#x02010;8</bold> also exhibited high selectivity against class IIa HDACs (HDAC4, HDAC5, HDAC7, and HDAC9) and class IV HDAC (HDAC11). These results suggest that <bold>SDFZ&#x02010;8</bold> represents a highly potent HDAC1/2/6 inhibitor with improved isoform selectivity compared with <bold>SAHA</bold>.</p><table-wrap position="float" id="mco270500-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>HDAC isoform selectivity of <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold>.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr><th colspan="2" style="border-bottom:solid 1px #000000" rowspan="2" align="left">HDAC isozymes</th><th colspan="3" style="border-bottom:solid 1px #000000" align="center" rowspan="1">IC<sub>50</sub> values (nM)<xref rid="mco270500-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" rowspan="1" colspan="1">SDFZ&#x02010;8</th><th align="center" rowspan="1" colspan="1">SAHA</th></tr></thead><tbody><tr><td rowspan="4" align="left" colspan="1">Class I</td><td align="center" rowspan="1" colspan="1">HDAC1</td><td align="center" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">37&#x000a0;&#x000b1;&#x000a0;7</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC2</td><td align="center" rowspan="1" colspan="1">5.8&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="center" rowspan="1" colspan="1">15.2&#x000a0;&#x000b1;&#x000a0;1.9</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC3</td><td align="center" rowspan="1" colspan="1">300&#x000a0;&#x000b1;&#x000a0;100</td><td align="center" rowspan="1" colspan="1">45&#x000a0;&#x000b1;&#x000a0;20</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC8</td><td align="center" rowspan="1" colspan="1">750&#x000a0;&#x000b1;&#x000a0;70</td><td align="center" rowspan="1" colspan="1">6400&#x000a0;&#x000b1;&#x000a0;600</td></tr><tr><td rowspan="4" align="left" colspan="1">Class IIa</td><td align="center" rowspan="1" colspan="1">HDAC4</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC5</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC7</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC9</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td></tr><tr><td rowspan="2" align="left" colspan="1">Class IIb</td><td align="center" rowspan="1" colspan="1">HDAC6</td><td align="center" rowspan="1" colspan="1">3.1&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="center" rowspan="1" colspan="1">90&#x000a0;&#x000b1;&#x000a0;7</td></tr><tr><td align="center" rowspan="1" colspan="1">HDAC10</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="center" rowspan="1" colspan="1">100&#x000a0;&#x000b1;&#x000a0;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Class IV</td><td align="center" rowspan="1" colspan="1">HDAC11</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td><td align="center" rowspan="1" colspan="1">&#x0003e;10,000</td></tr></tbody></table><table-wrap-foot><fn id="mco270500-tbl1-note-0001"><label>
<sup>a</sup>
</label><p>Results are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SD of three separate determinations.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="mco270500-sec-0050"><label>2.3</label><title>SDFZ&#x02010;8 Stimulates the Acetylation of Histone H3 and &#x003b1;&#x02010;Tubulin</title><p>To confirm the HDAC inhibitory effect of <bold>SDFZ&#x02010;8</bold> at the cellular level, western blotting was conducted on MDA&#x02010;MB&#x02010;231 cells. As illustrated in Figure&#x000a0;<xref rid="mco270500-fig-0001" ref-type="fig">1D</xref>, compound <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold> both displayed an upregulation in the level of acetylated histone H3 (Ac&#x02010;H3), a key substrate of class I HDACs. Moreover, <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold> exhibited an upregulation in the level of acetylated tubulin (Ac&#x02010;tubulin), which is a substrate of HDAC6. These results indicated that <bold>SDFZ&#x02010;8</bold> has the capability to inhibit class I HDACs (HDAC1, HDAC2, and HDAC3) as well as HDAC6 in MDA&#x02010;MB&#x02010;231 cells. In addition, we conducted immunofluorescence experiments to further investigate the accumulation of ac&#x02010;H3. As depicted in Figure&#x000a0;<xref rid="mco270500-fig-0001" ref-type="fig">1E</xref>, the immunofluorescence intensities of ac&#x02010;H3 in MDA&#x02010;MB&#x02010;231 cells treated with <bold>SDFZ&#x02010;8</bold> were notably stronger than those of cells treated with <bold>SAHA</bold>, consistent with the immunoblotting results. To further assess the cellular distribution of ac&#x02010;H3, we analyzed the colocalization of ac&#x02010;H3 and DAPI (a nuclear dye). The Pearson's <italic toggle="yes">R</italic> value and the overlap <italic toggle="yes">R</italic> value of ac&#x02010;H3 immunofluorescence and DAPI were determined to be 0.86 and 0.88, indicating a strong correlation between ac&#x02010;H3 and the nucleus (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S3</xref>).</p></sec><sec id="mco270500-sec-0060"><label>2.4</label><title>In Vitro Antiproliferative Activities of SDFZ&#x02010;8</title><p>Nine different human cancer cell lines were selected, including multiple myeloma cells RPMI&#x02010;8226, NCI&#x02010;H929, and KM3, acute promyelocytic leukemia cells HL&#x02010;60, T lymphocytic leukemia cells Jurkat, as well as solid tumor cell lines AGS, MDA&#x02010;MB&#x02010;231, MCF&#x02010;7, and PC&#x02010;3, to assess the antiproliferative potencies of <bold>SDFZ&#x02010;8</bold> (Table <xref rid="mco270500-supinfo-0001" ref-type="">S1</xref> and Figure <xref rid="mco270500-supinfo-0001" ref-type="">S4</xref>). As shown in Figure&#x000a0;<xref rid="mco270500-fig-0002" ref-type="fig">2A</xref>, <bold>SDFZ&#x02010;8</bold> exhibited superior antiproliferative activity (threefold to ninefold) compared with <bold>SAHA</bold>. It is worth noting that the limited efficacy of approved HDAC inhibitors against solid tumor cells as compared with hematologic neoplasm cells has constrained their clinical application [<xref rid="mco270500-bib-0029" ref-type="bibr">29</xref>]. As depicted in Figure&#x000a0;<xref rid="mco270500-fig-0002" ref-type="fig">2A</xref>, our newly designed compound <bold>SDFZ&#x02010;8</bold> demonstrated enhanced antiproliferative activity against solid tumor cells, including AGS, PC&#x02010;3, MDA&#x02010;MB&#x02010;231, and MCF&#x02010;7 cells. Triple&#x02010;negative breast cancer cells (MDA&#x02010;MB&#x02010;231) represent one of the most resistant types of breast cancer. Notably, <bold>SDFZ&#x02010;8</bold> exhibited threefold better antiproliferation activity than <bold>SAHA</bold> in MDA&#x02010;MB&#x02010;231 cells (Figure&#x000a0;<xref rid="mco270500-fig-0002" ref-type="fig">2B</xref>). To further explore antiproliferative activities of <bold>SDFZ&#x02010;8</bold>, the colony formation assay and EdU assay were performed. As shown in Figure&#x000a0;<xref rid="mco270500-fig-0002" ref-type="fig">2C</xref>, <bold>SDFZ&#x02010;8</bold> significantly inhibited the colony formation of MDA&#x02010;MB&#x02010;231. Besides, <bold>SDFZ&#x02010;8</bold> also decreased the EdU positive cells (Figure&#x000a0;<xref rid="mco270500-fig-0002" ref-type="fig">2D</xref>). The results confirmed the antiproliferative potencies of <bold>SDFZ&#x02010;8</bold>.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0002"><label>FIGURE 2</label><caption><p>
<bold>SDFZ&#x02010;8</bold> exhibits potent antiproliferative effects across cancer cell lines. (A) The antiproliferative activity of <bold>SDFZ&#x02010;8</bold> and SAHA against different tumor cell lines after 48&#x000a0;h treatment. The pIC<sub>50</sub> value was calculated as the negative logarithm of the IC<sub>50</sub> in molar concentration. (B) The dose&#x02010;dependent inhibition curve of <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold> on the cell viability of MDA&#x02010;MB&#x02010;231 cell of three separate determinations. (C) The clonogenic ability of MDA&#x02010;MB&#x02010;231 cells after treatment with 2&#x000a0;&#x000b5;M <bold>SDFZ&#x02010;8</bold> and 2&#x000a0;&#x000b5;M <bold>SAHA</bold> for 48&#x000a0;h. (D) The EdU staining results of MDA&#x02010;MB&#x02010;231 cells incubated with 2&#x000a0;&#x000b5;M <bold>SDFZ&#x02010;8</bold> and 2&#x000a0;&#x000b5;M <bold>SAHA</bold> for 24&#x000a0;h.</p></caption><graphic xlink:href="MCO2-6-e70500-g002" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="mco270500-sec-0070"><label>2.5</label><title>Effect of SDFZ&#x02010;8 on Cell Apoptosis</title><p>We examined the effects of <bold>SDFZ&#x02010;8</bold> on the apoptosis using the Annexin V&#x02010;FITC/PI method, which quantitatively determines the levels of apoptotic cells. As illustrated in Figure&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3A,B</xref>, the apoptosis promotion induced by <bold>SDFZ&#x02010;8</bold> was found to be superior to that of <bold>SAHA</bold>. Meanwhile, the TdT&#x02010;mediated dUTP nick&#x02010;end labeling (TUNEL) assay was also utilized to further assess the effects of HDAC inhibitors on cell apoptosis. In brief, MDA&#x02010;MB&#x02010;231 cells were exposed to different HDAC inhibitors for 24 h, stained with the FITC&#x02010;TUNEL kit, and imaged using a confocal laser scanning microscope.&#x000a0;As demonstrated in Figure&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3C,D</xref>, the treatment with <bold>SDFZ&#x02010;8</bold> led to a higher intensity of green fluorescence compared with <bold>SAHA</bold>. We utilized the GreenNuc assay to determine the level of caspase&#x02010;3 activation, which is an essential hallmark of cell apoptosis, in MDA&#x02010;MB&#x02010;231 cells. As depicted in Figure&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3E</xref>, <bold>SDFZ&#x02010;8</bold> induced caspase&#x02010;3 activation in a dose&#x02010;dependent manner, which is significantly higher than that observed for <bold>SAHA</bold>.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0003"><label>FIGURE 3</label><caption><p>
<bold>SDFZ&#x02010;8</bold> induces apoptosis and suppresses tumor growth in vivo. (A) Annexin V&#x02010;FITC/PI dual dying results of MDA&#x02010;MB&#x02010;231 cells incubated with selected compounds for 24&#x000a0;h. (B) Statistical analysis of apoptosis induced in MDA&#x02010;MB&#x02010;231 by selected compounds in Annexin V&#x02010;FITC/PI assay. (C) TUNEL dying results of MDA&#x02010;MB&#x02010;231 incubated with 5&#x000a0;&#x000b5;M selected compounds for 24&#x000a0;h. (D) Statistical analysis of apoptosis induced in MDA&#x02010;MB&#x02010;231 by selected compounds in TUNEL assay. (E) Caspase&#x02010;3 activation of MDA&#x02010;MB&#x02010;231 cells after treatment with indicated compounds for 24&#x000a0;h of three separate determinations detected by GreenNuc assay. (F) The levels of Bcl&#x02010;2, Bax, Caspase&#x02010;3/cleaved&#x02010;Caspase&#x02010;3 and PARP1/cleaved&#x02010;PARP1 in MDA&#x02010;MB&#x02010;231 cells after <bold>SDFZ&#x02010;8</bold> treatment for 24&#x000a0;h. (G) In vivo tumor growth inhibition of <bold>SDFZ&#x02010;8</bold> in the MDA&#x02010;MB&#x02010;231 xenograft model (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;3). (H) Hematoxylin&#x02013;eosin staining results of the lung, kidney, liver, heart and spleen. (****<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001&#x000a0;vs. vehicle; ##<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01&#x000a0;vs. <bold>SDFZ&#x02010;8</bold>).</p></caption><graphic xlink:href="MCO2-6-e70500-g001" position="anchor" id="jats-graphic-7"/></fig><p>Given the established roles of the Bcl&#x02010;2 family and caspase&#x02010;3 in HDAC inhibitor&#x02010;induced apoptosis, we examined the expression of relevant proteins. The results demonstrated that <bold>SDFZ&#x02010;8</bold> treatment upregulated the proapoptotic protein Bax while downregulating the antiapoptotic protein Bcl&#x02010;2 (Figure&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3F</xref>), suggesting a shift in the cellular balance toward apoptosis. Moreover, we detected an increase in the levels of cleaved caspase&#x02010;3 and cleaved PARP, upon <bold>SDFZ&#x02010;8</bold> treatment (Figure&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3F</xref>). These results mentioned above clearly indicate that apoptosis in MDA&#x02010;MB&#x02010;231 cells was significantly induced by our newly designed HDAC inhibitor.</p></sec><sec id="mco270500-sec-0080"><label>2.6</label><title>Preliminary Pharmacokinetic Study of SDFZ&#x02010;8</title><p>Based on the results of in vitro HDAC inhibition and antiproliferation activity, <bold>SDFZ&#x02010;8</bold> was chosen for further pharmacokinetic assessment. In mouse liver microsomes (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S5</xref>), <bold>SDFZ&#x02010;8</bold> displayed improved metabolic stability compared with <bold>SAHA</bold>, characterized by a longer half&#x02010;life (<italic toggle="yes">T</italic>
<sub>1/2</sub>&#x000a0;=&#x000a0;12.31&#x000a0;min) and a lower intrinsic clearance rate (CL<sub>int(mic)</sub>&#x000a0;=&#x000a0;56.28&#x000a0;&#x000b5;L/min/mg). Subsequently, <bold>SDFZ&#x02010;8</bold> was administered intravenously (i.v.) at 2.5&#x000a0;mg/kg or orally (i.g.) at 10&#x000a0;mg/kg using male Sprague&#x02013;Dawley (SD) rats to evaluate its in vivo pharmacokinetic properties. As shown in Table&#x000a0;<xref rid="mco270500-tbl-0002" ref-type="table">2</xref>, <bold>SDFZ&#x02010;8</bold> demonstrated a satisfactory half&#x02010;life (i.v., <italic toggle="yes">T</italic>
<sub>1/2</sub>&#x000a0;=&#x000a0;2.29&#x000a0;h; i.g., <italic toggle="yes">T</italic>
<sub>1/2</sub>&#x000a0;=&#x000a0;5.74&#x000a0;h), maximum plasma concentration (i.v., <italic toggle="yes">C</italic>
<sub>max</sub>&#x000a0;=&#x000a0;1750&#x000a0;ng/mL; i.g., <italic toggle="yes">C</italic>
<sub>max</sub>&#x000a0;=&#x000a0;658.8&#x000a0;ng/mL), and drug exposure (i.v., AUC<sub>0&#x02212;</sub>
<italic toggle="yes">
<sub>t</sub>
</italic>&#x000a0;=&#x000a0;2729&#x000a0;ng/mL&#x000a0;h; i.g., AUC<sub>0&#x02212;</sub>
<italic toggle="yes">
<sub>t</sub>
</italic>&#x000a0;=&#x000a0;3084&#x000a0;ng/mL&#x000a0;h). The oral bioavailability of <bold>SDFZ&#x02010;8</bold> was determined to be 26.11%, signaling its viability as a suitable dosing route for further in vivo investigations.</p><table-wrap position="float" id="mco270500-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>In vivo pharmacokinetic parameters of <bold>SDFZ&#x02010;8</bold>.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">PK parameters</th><th align="center" rowspan="1" colspan="1">i.v. (2.5&#x000a0;mg/kg)<xref rid="mco270500-tbl2-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">i.g. (10&#x000a0;mg/kg)<xref rid="mco270500-tbl2-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>1/2</sub> (h)</td><td align="center" rowspan="1" colspan="1">2.29&#x000a0;&#x000b1;&#x000a0;1.24</td><td align="center" rowspan="1" colspan="1">5.74&#x000a0;&#x000b1;&#x000a0;1.51</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub> (h)</td><td align="center" rowspan="1" colspan="1">0.08&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="center" rowspan="1" colspan="1">0.33&#x000a0;&#x000b1;&#x000a0;0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (ng/mL)</td><td align="center" rowspan="1" colspan="1">1750&#x000a0;&#x000b1;&#x000a0;498.0</td><td align="center" rowspan="1" colspan="1">658.8&#x000a0;&#x000b1;&#x000a0;63.09</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02212;</sub>
<italic toggle="yes">
<sub>t</sub>
</italic> (ng/mL&#x000a0;h)</td><td align="center" rowspan="1" colspan="1">2729&#x000a0;&#x000b1;&#x000a0;259.8</td><td align="center" rowspan="1" colspan="1">3084&#x000a0;&#x000b1;&#x000a0;205.9</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0&#x02212;</sub>
<italic toggle="yes">
<sub>&#x0221e;</sub>
</italic> (ng/mL&#x000a0;h)</td><td align="center" rowspan="1" colspan="1">3121&#x000a0;&#x000b1;&#x000a0;241.6</td><td align="center" rowspan="1" colspan="1">3259&#x000a0;&#x000b1;&#x000a0;662.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">F</italic>%</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">26.11%</td></tr></tbody></table><table-wrap-foot><fn id="mco270500-tbl2-note-0001"><label>
<sup>a</sup>
</label><p>All experiments are expressed as the mean &#x000b1; standard deviation of three separate determinations (mean&#x000a0;&#x000b1;&#x000a0;SD).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="mco270500-sec-0090"><label>2.7</label><title>In Vivo Antitumor Activity of SDFZ&#x02010;8 in the MDA&#x02010;MB&#x02010;231 Xenograft Model</title><p>To assess the in vivo antitumor efficacy of <bold>SDFZ&#x02010;8</bold>, we established a xenograft model in nude mice (BALB/c&#x02010;nu) using MDA&#x02010;MB&#x02010;231 cells. Specifically, 1.1&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup> MDA&#x02010;MB&#x02010;231 cells were subcutaneously injected, and when the tumor size reached approximately 100&#x000a0;mm<sup>3</sup>, <bold>SDFZ&#x02010;8</bold> (60&#x000a0;mg/kg/day) or <bold>SAHA</bold> (60&#x000a0;mg/kg/day) were administered via oral gavage for 22 days. As illustrated in Figure&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3G</xref>, both <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold> significantly suppressed tumor growth compared with the vehicle group (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). It is worth noting that <bold>SDFZ&#x02010;8</bold> (TGI&#x000a0;=&#x000a0;76%) demonstrated superior in vivo antitumor activity compared with <bold>SAHA</bold> (TGI&#x000a0;=&#x000a0;60%) (<bold>Table</bold>
<xref rid="mco270500-supinfo-0001" ref-type="">
<bold>S2</bold>
</xref>). Collectively, <bold>SDFZ&#x02010;8</bold> effectively suppressed tumor growth in MDA&#x02010;MB&#x02010;231 xenograft BALB/c&#x02010;nu mice without adversely affecting the general health of the mice (Figures&#x000a0;<xref rid="mco270500-fig-0003" ref-type="fig">3H</xref> and <xref rid="mco270500-supinfo-0001" ref-type="">S6A</xref>).</p></sec><sec id="mco270500-sec-0100"><label>2.8</label><title>SDFZ&#x02010;8 Upregulates PD&#x02010;L1 Expression by Inhibition of HDAC1</title><p>Previous studies have highlighted the essential role of HDACs as epigenetic modulators of tumor immunity and indicated promising potential for cancer immunotherapy with HDAC inhibitors [<xref rid="mco270500-bib-0030" ref-type="bibr">30</xref>, <xref rid="mco270500-bib-0031" ref-type="bibr">31</xref>, <xref rid="mco270500-bib-0032" ref-type="bibr">32</xref>, <xref rid="mco270500-bib-0033" ref-type="bibr">33</xref>, <xref rid="mco270500-bib-0034" ref-type="bibr">34</xref>]. Specifically, it has been reported that HDAC inhibitors could elevate the expression level of PD&#x02010;L1 in melanoma, thereby enhancing immunotherapy with PD&#x02010;1 blockade [<xref rid="mco270500-bib-0035" ref-type="bibr">35</xref>]. These findings underscore the potential involvement of HDACs in the regulation of the PD&#x02010;1/PD&#x02010;L1 signaling pathway. Using flow cytometry, we also observed an increase in PD&#x02010;L1 expression following treatment with <bold>SDFZ&#x02010;8</bold> in MDA&#x02010;MB&#x02010;231 cells (Figure&#x000a0;<xref rid="mco270500-fig-0004" ref-type="fig">4A</xref>). These results further support the potential of <bold>SDFZ&#x02010;8</bold> in modulating the PD&#x02010;1/PD&#x02010;L1 axis with potential implications for cancer immunotherapy. Given the strong evidence supporting <bold>SDFZ&#x02010;8</bold> as a potent HDAC1 inhibitor, we pursued further investigation into the role of HDAC1 in stimulating PD&#x02010;L1 expression. As depicted in Figure&#x000a0;<xref rid="mco270500-fig-0004" ref-type="fig">4A<bold>&#x02013;C</bold>
</xref>, knockdown of HDAC1 led to an increase in PD&#x02010;L1 expression in MDA&#x02010;MB&#x02010;231 cells, and treatment of <bold>SDFZ&#x02010;8</bold> in HDAC1&#x02010;knockdown MDA&#x02010;MB&#x02010;231 cells did not yield a further increase in PD&#x02010;L1 expression. These findings strongly suggest that <bold>SDFZ&#x02010;8</bold> has the capacity to upregulate PD&#x02010;L1 expression by specifically inhibiting HDAC1, thereby implying the potential for combined use with anti&#x02010;PD&#x02010;1 or anti&#x02010;PD&#x02010;L1 blockade therapies.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0004"><label>FIGURE 4</label><caption><p>
<bold>SDFZ&#x02010;8</bold> promotes immune activation and synergizes with anti&#x02010;PD&#x02010;L1 therapy in the MC38 model. (A&#x02013;C) Impacts of HDAC1 inhibition on PD&#x02010;L1 expression in MDA&#x02010;MB&#x02010;231 cells and knockdown of HDAC1 using shRNA virus infected for 96&#x000a0;h. (D) Treatment with the HDAC1 inhibitor <bold>SDFZ&#x02010;8</bold> for 24&#x000a0;h upregulates PD&#x02010;L1 expression in MC38 cells of four separate determinations (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;4/each group). (E) In vivo antitumor potency of <bold>SDFZ&#x02010;8</bold> in the MC38 syngeneic model (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;5/each group). (F) Comparison of the tumor growth suppression and PD&#x02010;L1 regulation between <bold>SAHA</bold> and <bold>SDFZ&#x02010;8</bold> in combination with anti&#x02010;PD&#x02010;L1 blockade (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;6/each group). (****<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, **<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, *<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05&#x000a0;vs. vehicle; ##<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.01, #<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.05&#x000a0;vs. <bold>SDFZ&#x02010;8</bold>).</p></caption><graphic xlink:href="MCO2-6-e70500-g006" position="anchor" id="jats-graphic-9"/></fig></sec><sec id="mco270500-sec-0110"><label>2.9</label><title>SDFZ&#x02010;8 Augment Tumor Immunity and Synergetic with Anti&#x02010;PD&#x02010;L1 Blockade in the MC38 Syngeneic Model</title><p>Treatment of <bold>SDFZ&#x02010;8</bold> also increased the expression level of PD&#x02010;L1 in MC38 cells (Figure&#x000a0;<xref rid="mco270500-fig-0004" ref-type="fig">4D</xref>). To gain further insights into the immune modulation effects of <bold>SDFZ&#x02010;8</bold> in vivo, we utilized the MC38 syngeneic C57BL/6J mice model and treated them with <bold>SAHA</bold>, <bold>SDFZ&#x02010;8</bold>, anti&#x02010;PD&#x02010;L1 blockade, and a combination of <bold>SDFZ&#x02010;8</bold> and anti&#x02010;PD&#x02010;L1 blockade. As demonstrated in Figure&#x000a0;<xref rid="mco270500-fig-0004" ref-type="fig">4E</xref>, the treatment with <bold>SDFZ&#x02010;8</bold> led to a significant reduction in tumor volume and tumor weight compared with the vehicle group, thereby confirming the in vivo antitumor efficacy of <bold>SDFZ&#x02010;8</bold>. Furthermore, our results indicated that <bold>SDFZ&#x02010;8</bold> (TGI&#x000a0;=&#x000a0;71%) exhibited greater potency than <bold>SAHA</bold> (TGI&#x000a0;=&#x000a0;50%), a finding consistent with the results from the xenograft model. In particular, the combined use of <bold>SDFZ&#x02010;8</bold> with anti&#x02010;PD&#x02010;L1 blockade (atezolizumab) produced more potent antitumor effects (TGI&#x000a0;=&#x000a0;86%) than monotherapy (TGI&#x000a0;=&#x000a0;64%) (<bold>Table</bold>
<xref rid="mco270500-supinfo-0001" ref-type="">
<bold>S2</bold>
</xref>). No significant changes in body weight were observed during the administration period (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S6B</xref>). Furthermore, our hematoxylin&#x02013;eosin (H&#x00026;E) staining analysis indicated that <bold>SDFZ&#x02010;8</bold> exhibited low toxicity in various organs (heart, liver, spleen, lung, and kidney) and exerted significant antitumor effects in tumor tissue (<bold>Figure</bold>
<xref rid="mco270500-supinfo-0001" ref-type="">
<bold>S7</bold>
</xref>). The comparison of the antitumor effects of <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold> in combination with anti&#x02010;PD&#x02010;L1 blockade revealed that the <bold>SDFZ&#x02010;8&#x000a0;</bold>+&#x000a0;anti&#x02010;PD&#x02010;L1 group displayed superior antitumor activity compared with the <bold>SAHA&#x000a0;</bold>+&#x000a0;anti&#x02010;PD&#x02010;L1 group (Figure&#x000a0;<xref rid="mco270500-fig-0004" ref-type="fig">4F</xref>). Notably, we also observed higher PD&#x02010;L1 expression levels in the <bold>SDFZ&#x02010;8&#x000a0;</bold>+&#x000a0;anti&#x02010;PD&#x02010;L1 group than in the <bold>SAHA&#x000a0;</bold>+&#x000a0;anti&#x02010;PD&#x02010;L1 group.</p></sec><sec id="mco270500-sec-0120"><label>2.10</label><title>SDFZ&#x02010;8 Stimulates Potent Antitumor Immunity</title><p>To assess the impact of <bold>SDFZ&#x02010;8</bold> on tumor immunity, we conducted measurements of the composition and functional levels of different immune cells using flow cytometry. Activated T cells play a crucial role in antitumor immunity. As illustrated in Figure&#x000a0;<xref rid="mco270500-fig-0005" ref-type="fig">5A</xref>, treatment with <bold>SDFZ&#x02010;8</bold> resulted in a more significant increase in tumor&#x02010;infiltrating lymphocytes (TILs) than <bold>SAHA</bold>, particularly in the populations of CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells. Both <bold>SAHA</bold> and <bold>SDFZ&#x02010;8</bold> demonstrated an upregulation in the expression levels of functional molecules associated with T cell activation, including IFN&#x02010;&#x003b3; and TNF&#x02010;&#x003b1;, in CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells. Additionally, the proportion of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and NK cells was elevated in the spleen following treatment with <bold>SDFZ&#x02010;8</bold>, whereas <bold>SAHA</bold> did not induce such effects (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S8</xref>). These findings strongly indicate that <bold>SDFZ&#x02010;8</bold> enhances antitumor immunity by promoting T cell activation.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0005"><label>FIGURE 5</label><caption><p>
<bold>SDFZ&#x02010;8</bold> enhances antitumor immunity through immune cell modulation. (A) Impacts of <bold>SDFZ&#x02010;8</bold> on the T cell infiltration and activation of five separate determinations. (B) Impacts of <bold>SDFZ&#x02010;8</bold> on macrophage cells in the tumor environment of five separate determinations. (C) Impacts of <bold>SDFZ&#x02010;8</bold> on MHC II expression in macrophages and DCs of five separate determinations. (D) Impacts of <bold>SDFZ&#x02010;8</bold> on PD&#x02010;1 and PD&#x02010;L1 expression in tumor&#x02010;infiltrating immune cells and spleen immune cells of five separate determinations. <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;6/each group. (****<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.0001, ***<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001, **<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.01, *<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05&#x000a0;vs. vehicle; ####<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, ###<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, ##<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.01&#x000a0;vs. <bold>SAHA</bold>).</p></caption><graphic xlink:href="MCO2-6-e70500-g005" position="anchor" id="jats-graphic-11"/></fig><p>On the other hand, tumor&#x02010;associated macrophages (TAMs) are among the major tumor&#x02010;infiltrating immune cells and are generally categorized into two primary phenotypes, M1 and M2. Previous research suggests that M1 TAMs can suppress cancer progression, while M2 TAMs exhibit the opposite effect [<xref rid="mco270500-bib-0036" ref-type="bibr">36</xref>]. Our analysis, which involved the detection of specific markers for M1&#x02010;type macrophages (iNOS [<xref rid="mco270500-bib-0037" ref-type="bibr">37</xref>]) and M2&#x02010;type macrophages (CD206<sup>38</sup>), revealed that the percentage of M2 TAMs in TILs was over 65% in the vehicle group, indicating a tumor&#x02010;promoting microenvironment (Figure&#x000a0;<xref rid="mco270500-fig-0005" ref-type="fig">5B</xref>). Notably, both <bold>SDFZ&#x02010;8</bold> and <bold>SAHA</bold> robustly promoted M1 polarization and suppressed the M2 polarization of TAMs. Additionally, the recognition and presentation of tumor antigens are crucial for eliciting antitumor immunity. Dendritic cells (DCs) and macrophages are essential antigen&#x02010;presenting cells responsible for recognizing and presenting tumor antigens. Our findings illustrated in Figure&#x000a0;<xref rid="mco270500-fig-0005" ref-type="fig">5C</xref> indicate that treatment with <bold>SDFZ&#x02010;8</bold> significantly increased the surface expression of MHC class II (MHC II) in both DCs and macrophages, while <bold>SAHA</bold> only impacted MHC II in DCs.</p><p>The results from our in vitro experiments indicating that <bold>SDFZ&#x02010;8</bold> upregulates PD&#x02010;L1 expression in MC38 cells (Figure&#x000a0;<xref rid="mco270500-fig-0004" ref-type="fig">4D</xref>) were consistently reflected in the in vivo experiment, where treatment with <bold>SDFZ&#x02010;8</bold> led to an upregulation in the expression of PD&#x02010;L1 in tumor&#x02010;infiltrating immune cells (DCs and macrophages) (Figure&#x000a0;<xref rid="mco270500-fig-0005" ref-type="fig">5D</xref>). Interestingly, <bold>SDFZ&#x02010;8</bold> did not affect PD&#x02010;1 expression in tumor&#x02010;infiltrating CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells, and downregulated PD&#x02010;1 expression in tumor&#x02010;infiltrating NK cells. Furthermore, <bold>SDFZ&#x02010;8</bold> significantly decreased PD&#x02010;L1 and PD&#x02010;1 expression in various immune cells in the spleen. In contrast, the pan&#x02010;HDAC inhibitor <bold>SAHA</bold> upregulated both PD&#x02010;L1 and PD&#x02010;1 expression in tumor&#x02010;infiltrating immune cells. In the spleen, <bold>SAHA</bold> upregulated PD&#x02010;L1 expression in DCs and macrophages and downregulated PD&#x02010;1 expression in CD4<sup>+</sup> T cells and NK cells. Consequently, the nonselective HDAC inhibitor enhanced PD&#x02010;1/PD&#x02010;L1 signaling and indicated an immunosuppressive role. Our newly designed high&#x02010;potency and HDAC1/2/6 selective inhibitor, <bold>SDFZ&#x02010;8</bold>, specifically upregulated PD&#x02010;L1 expression and downregulated PD&#x02010;1 expression in tumor&#x02010;infiltrating and spleen immune cells, suggesting its potential to enhance the efficacy of anti&#x02010;PD&#x02010;L1 blockade without promoting immunosuppression effects mediated by PD&#x02010;1/PD&#x02010;L1 signaling.</p></sec><sec id="mco270500-sec-0130"><label>2.11</label><title>SDFZ&#x02010;8 Augment Tumor Immunity and Synergetic with Anti&#x02010;PD&#x02010;L1 Blockade in the B16F10 Syngeneic Model</title><p>To substantiate the therapeutic potential of <bold>SDFZ&#x02010;8</bold> across broader cancer types, we conducted validation studies using the B16F10 xenograft melanoma model. As shown in Figure&#x000a0;<xref rid="mco270500-fig-0006" ref-type="fig">6A&#x02013;E</xref> and <bold>Table</bold>
<xref rid="mco270500-supinfo-0001" ref-type="">
<bold>S2</bold>
</xref>, <bold>SDFZ&#x02010;8</bold> significantly reduced tumor volume and tumor weight (TGI&#x000a0;=&#x000a0;75%) compared with the other single HDAC inhibitor treatment group. Furthermore, the combination of <bold>SDFZ&#x02010;8</bold> with anti&#x02010;PD&#x02010;L1 blockade produced more potent antitumor effects (TGI = 91%) than monotherapy and the combination of other HDAC inhibitors with anti&#x02010;PD&#x02010;L1 blockade. No significant changes in body weight were observed during the administration period. (Figure <xref rid="mco270500-supinfo-0001" ref-type="">S6C</xref>) These investigations confirmed the efficacy of <bold>SDFZ&#x02010;8</bold> in suppressing melanoma progression and revealed synergistic tumor growth inhibition when administered in combination with anti&#x02010;PD&#x02010;L1 immunotherapy.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0006"><label>FIGURE 6</label><caption><p>
<bold>SDFZ&#x02010;8</bold> synergizes with anti&#x02010;PD&#x02010;L1 to inhibit tumor growth in the B16F10 melanoma model. (A and B) The curves of tumor volumes (A) and body weights (B) of mice treated with indicated compounds combined with or without anti&#x02010;PD&#x02010;L1 blockade in the B16F10 syngeneic model. (C and D) The weights (C) and representative images (D) of tumors in the B16F10 syngeneic model. (E) The tumor volume curves of each mouse in different groups in the B16F10 syngeneic model. <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;5/each group. (****<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, **<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01&#x000a0;vs. vehicle; ####<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.0001, ###<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001&#x000a0;vs. <bold>SDFZ&#x02010;8</bold>).</p></caption><graphic xlink:href="MCO2-6-e70500-g007" position="anchor" id="jats-graphic-13"/></fig></sec></sec><sec id="mco270500-sec-0140"><label>3</label><title>Discussion</title><p>In this study, a new series of quinolone&#x02010;based HDAC inhibitors were designed using fragment&#x02010;centric pocket analysis. Among them, <bold>SDFZ&#x02010;8</bold> was identified as the most active compound, demonstrating potent inhibition of HDAC1/2/6 (IC<sub>50</sub>&#x000a0;=&#x000a0;0.4&#x02013;5.8&#x000a0;nM) and selective over other HDAC isoforms. Additionally, <bold>SDFZ&#x02010;8</bold> exhibited superior antiproliferative activity against various tumor cells compared with the positive control drug SAHA. In MDA&#x02010;MB&#x02010;231 cells, <bold>SDFZ&#x02010;8</bold> promoted acetylation of histone H3 and significantly induced cell apoptosis. Preliminary pharmacokinetic studies indicated liver microsome stability and oral bioavailability of <bold>SDFZ&#x02010;8</bold>. Furthermore, <bold>SDFZ&#x02010;8</bold> effectively reduced tumor burden in both the MDA&#x02010;MB&#x02010;231 xenograft model and the MC38 syngeneic model, surpassing the performance of SAHA.</p><p>In comparison with nonselective HDAC inhibitors, our newly designed HDAC1/2/6 inhibitor, <bold>SDFZ&#x02010;8</bold>, not only demonstrated more potent T cell activation and improved antigen presenting ability but also contributed to alleviating the immunosuppressive tumor environment by promoting macrophage polarization and negatively regulating PD&#x02010;1 expression (Figure&#x000a0;<xref rid="mco270500-fig-0007" ref-type="fig">7</xref>). Interestingly, <bold>SDFZ&#x02010;8</bold> has demonstrated a notable ability to elevate PD&#x02010;L1 expression in both in vitro and in vivo studies, which is closely related to its potent inhibitory effect on HDAC1.&#x000a0;The upregulation of PD&#x02010;L1 levels facilitates the antitumor immune therapeutic activity of PD&#x02010;L1 blockade and we observed increased antitumor efficacy of <bold>SDFZ&#x02010;8</bold> when used in combination with PD&#x02010;L1 blockade.</p><fig position="float" fig-type="FIGURE" id="mco270500-fig-0007"><label>FIGURE 7</label><caption><p>Proposed mechanism of action of <bold>SDFZ&#x02010;8</bold> in stimulating antitumor immunity.</p></caption><graphic xlink:href="MCO2-6-e70500-g008" position="anchor" id="jats-graphic-15"/></fig><p>The epigenetic regulation plays a pivotal role in modulating the tumor immune microenvironment. Prior studies have indicated that HDAC inhibitors exhibit immunomodulatory effects; however, the specific molecular mechanisms remain unclear [<xref rid="mco270500-bib-0039" ref-type="bibr">39</xref>, <xref rid="mco270500-bib-0040" ref-type="bibr">40</xref>, <xref rid="mco270500-bib-0041" ref-type="bibr">41</xref>, <xref rid="mco270500-bib-0042" ref-type="bibr">42</xref>, <xref rid="mco270500-bib-0043" ref-type="bibr">43</xref>, <xref rid="mco270500-bib-0044" ref-type="bibr">44</xref>, <xref rid="mco270500-bib-0045" ref-type="bibr">45</xref>]. Emerging evidence suggests broader HDAC&#x02010;PD&#x02010;L1 regulatory networks. HDAC3 enhances PD&#x02010;L1 expression via STAT3/NF&#x02010;&#x003ba;B signaling [<xref rid="mco270500-bib-0046" ref-type="bibr">46</xref>], while HDAC6 promotes PD&#x02010;L1 transcription through STAT3 phosphorylation [<xref rid="mco270500-bib-0047" ref-type="bibr">47</xref>]. In hepatocellular carcinoma, HDAC9 correlates with PD&#x02010;L1 overexpression though its mechanism remains unclear [<xref rid="mco270500-bib-0048" ref-type="bibr">48</xref>]. Recent research has elucidated that HDAC2, a member of the class I HDAC family, can impact tumor immune evasion by catalyzing the acetylation of PD&#x02010;L1, thus influencing its nuclear translocation [<xref rid="mco270500-bib-0017" ref-type="bibr">17</xref>]. HDAC5, a member of class II HDAC family, has been found to regulate PD&#x02010;L1 expression by stimulating p65 deacetylation in pancreatic cancer [<xref rid="mco270500-bib-0049" ref-type="bibr">49</xref>]. Our discovery that HDAC1 inhibition upregulates PD&#x02010;L1 adds another layer to this complex regulation, suggesting isoform&#x02010;specific targeting may differentially modulate immune checkpoint expression. Also, the newly designed HDAC1/2/6 inhibitor <bold>SDFZ&#x02010;8</bold> not only effectively upregulates PD&#x02010;L1 expression in tumor cells but also modulates lymphocyte expression of PD&#x02010;1 and PD&#x02010;L1, thereby alleviating the suppressive immune microenvironment and enhancing the therapeutic efficacy of anti&#x02010;PD&#x02010;L1 blockade.</p><p>This study has limitations that also present opportunities for future research. The broader inhibitory profile of <bold>SDFZ&#x02010;8</bold>, while central to its efficacy, precludes attribution of its effects to a single HDAC isoform. Consequently, the relative contribution of HDAC1/2 versus HDAC6 inhibition to the overall antitumor and immune&#x02010;modulating effects warrants further investigation. Additionally, the exact immune&#x02010;mediated mechanisms of action require deeper validation in immunocompetent settings. Despite these open questions, our findings robustly demonstrate that simultaneous targeting of these HDACs with <bold>SDFZ&#x02010;8</bold> yields potent antitumor activity and underscore the therapeutic promise of this strategy in oncology.</p></sec><sec id="mco270500-sec-0150"><label>4</label><title>Experimental</title><sec id="mco270500-sec-0160"><label>4.1</label><title>HDACs Enzymatic Assays</title><p>HDACs enzymatic assays were conducted according to our previous work [<xref rid="mco270500-bib-0050" ref-type="bibr">50</xref>]. In detail, the HeLa nuclear extract, HDAC1 (BPS BIOSCIENCE INC, 50051), HDAC2 (BPS BIOSCIENCE Inc; 50052), HDAC3/NCOR1 complex (BPS BIOSCIENCE Inc; 50003), HDAC4 (BPS BIOSCIENCE Inc; 50004), HDAC5 (BPS BIOSCIENCE Inc; 50005), HDAC6 (BPS BIOSCIENCE Inc; 50006), HDAC7 (BPS BIOSCIENCE Inc; 50007), HDAC8 (BPS BIOSCIENCE Inc; 50008), HDAC9 (BPS BIOSCIENCE Inc; 50009), HDAC10 (BPS BIOSCIENCE Inc; 50010), or HDAC11 (BPS BIOSCIENCE Inc; 50011) was diluted to the proper concentrations according to the relative enzymatic activity and the linear range of the plate reader and mixed with different concentrations of drugs. Substrates (Boc&#x02010;Lys(acetyl)&#x02010;AMC for HeLa nuclear extract, Ac&#x02010;Leu&#x02010;Gly&#x02010;Lys (Tfa)&#x02010;AMC for HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10, and HDAC11, Boc&#x02010;Lys(triflouroacetyl)&#x02010;AMC for HDAC8 and Ac&#x02010;Leu&#x02010;Gly&#x02010;Lys(acetyl)&#x02010;AMC for HDAC1, HDAC2, HDAC3) were added to the mixture. The blank group was set to no enzyme or drug but contains substrates and the control group was set to no drug but contains substrates and enzymes to each 96&#x02010;well plate. After 30&#x000a0;min of incubation at 37&#x000b0;C, the mixture was terminated with 1&#x000a0;mg/mL trypsin and 3&#x000a0;&#x000b5;M TSA. After another 30&#x000a0;min, the fluorescence intensity was measured using a Varioskan plate reader at 360/460&#x000a0;nm. The inhibition rate was calculated by the formula: inhibition rate (%)&#x000a0;=&#x000a0;(fluoresce of control group&#x000a0;&#x02212;&#x000a0;fluoresce of experiment group)/(fluoresce of control group&#x000a0;&#x02212;&#x000a0;fluoresce of blank group)&#x000a0;&#x000d7;&#x000a0;100%. The inhibition curves and IC<sub>50</sub> values were simulated and calculated using the log(inhibitor) versus response (three parameters) mode in GraphPad Prism software.</p></sec><sec id="mco270500-sec-0170"><label>4.2</label><title>Cell Culture and CCK&#x02010;8 Assay</title><p>Cell lines purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) were passaged after resuscitation. All cells in this work were cultured under 37&#x000b0;C and 5% CO<sub>2</sub> circumstance with RPMI&#x02010;1640 medium with 10% fetal bovine serum and 1% penicillin&#x02010;streptomycin (all purchased from Biological Industries Inc.). The third to tenth passages of cells were used for experiments. For the CCK&#x02010;8 assay, cells (4000 cells per well for solid tumors and 1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well for hematological tumors) were seeded in a 96&#x02010;well plate and incubated with different drugs for 48&#x000a0;h. After incubation, 20&#x000a0;&#x000b5;L CCK&#x02010;8 solution (MeilunBio) was added. Two hours later, absorption was measured by a Varioskan plate at 450&#x000a0;nm. Inhibition curves and IC<sub>50</sub> values were simulated and calculated using the log(inhibitor) versus response (three parameters) mode via GraphPad Prism software.</p></sec><sec id="mco270500-sec-0180"><label>4.3</label><title>Colony Formation Assay</title><p>The colony formation assay is performed by seeding 1000 MDA&#x02010;MB&#x02010;231 cells per well into 6&#x02010;well plates and allowing them to adhere overnight. After treatment with <bold>SDFZ&#x02010;8</bold> or <bold>SAHA</bold> for 48&#x000a0;h, cells are cultured for 14 days&#x0200b;&#x0200b; to form colonies. Once colonies are visible (&#x02265;50 cells per colony), the medium is removed, and cells are gently washed with PBS, fixed with &#x0200b;&#x0200b;4% paraformaldehyde for 15&#x000a0;min, and stained with &#x0200b;&#x0200b;Giemsa stain&#x0200b;&#x0200b; solution for 30&#x000a0;min. Excess stain is rinsed with water, and plates are air&#x02010;dried. Colonies are then imaged.</p></sec><sec id="mco270500-sec-0190"><label>4.4</label><title>EdU Assay</title><p>The EdU assay is performed by BeyoClick EdU kit. MDA&#x02010;MB&#x02010;231 cells were cultured in a 6&#x02010;well plate overnight. After treatment with <bold>SDFZ&#x02010;8</bold> or <bold>SAHA</bold> for 24&#x000a0;h, cells are labeled with a &#x0200b;&#x0200b;2&#x000d7;EdU working solution and incubated for &#x0200b;&#x0200b;2&#x000a0;h. Following labeling, cells are fixed with &#x0200b;&#x0200b;4% PFA for 15&#x000a0;min, washed three times with wash buffer, and permeabilized using &#x0200b;&#x0200b;0.3% Triton X&#x02010;100 for 15&#x000a0;min. After another wash, endogenous peroxidases are blocked for 20&#x000a0;min. For detection, a &#x0200b;&#x0200b;click reaction mix&#x0200b;&#x0200b; (containing Biotin Azide, CuSO<sub>4</sub>, and click additive) is added and incubated for 30&#x000a0;min. After washing, &#x0200b;&#x0200b;streptavidin&#x02013;HRP&#x0200b;&#x0200b; is applied and reacted for 30&#x000a0;min, followed by &#x0200b;&#x0200b;5&#x000a0;min DAB substrate&#x0200b; incubation&#x0200b;. Finally, cells are washed, optionally counterstained, and imaged under a microscope.</p></sec><sec id="mco270500-sec-0200"><label>4.5</label><title>TUNEL Assay</title><p>The TUNEL assay was performed with the one&#x02010;step TUNEL apoptosis kit (MeilunBio) according to the manual from the manufacturer [<xref rid="mco270500-bib-0050" ref-type="bibr">50</xref>, <xref rid="mco270500-bib-0051" ref-type="bibr">51</xref>]. Briefly, cells (5&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per plate) were seeded in confocal dishes and incubated with drugs for 24&#x000a0;h. The medium was removed, and cells were fixed with 4% polyoxymethylene solution for 30&#x000a0;min. Subsequently, cells were treated with 20&#x000a0;&#x000b5;g/mL protease K for 5&#x000a0;min and TUNEL working solution for 1&#x000a0;h at 37&#x000b0;C. Eventually, cells were captured with a Leica TCS SP8 super&#x02010;resolution laser scanning confocal microscope.</p></sec><sec id="mco270500-sec-0210"><label>4.6</label><title>Annexin V&#x02010;FITC/PI Dual Staining Assay</title><p>The dual staining apoptosis assay was performed with the Annexin V&#x02010;FITC/PI apoptosis kit, followed by the manufacturer's instructions [<xref rid="mco270500-bib-0050" ref-type="bibr">50</xref>, <xref rid="mco270500-bib-0051" ref-type="bibr">51</xref>, <xref rid="mco270500-bib-0052" ref-type="bibr">52</xref>]. Generally, cells (3&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were seeded in six&#x02010;well plates and treated with drugs for 24&#x000a0;h. After incubation, cells were harvested and dyed with Annexin V&#x02010;FITC and PI solutions for 15&#x000a0;min. Flow cytometry was performed to analyze cell apoptosis with a Beckman Coulter Gallios Flow Cytometer.</p></sec><sec id="mco270500-sec-0220"><label>4.7</label><title>GreenNuc Assay for the Detection of Caspase&#x02010;3 Activation</title><p>Caspase&#x02010;3 activation was detected with the GreenNuc caspase&#x02010;3 assay kit for live cells (Beyotime Inc). Cells (10<sup>5</sup> cells per well) were seeded in black 96&#x02010;well plates and treated with different concentrations of compounds. After 24&#x000a0;h, the medium was discarded, and cells were treated with GreenNuc caspase&#x02010;3 substrate at room temperature for 30&#x000a0;min. Fluorescence intensity was measured using a Varioskan plate reader at 485/515&#x000a0;nm, and the final activation folds were calculated.</p></sec><sec id="mco270500-sec-0230"><label>4.8</label><title>Molecular Docking and Pocket Calculations</title><p>
<italic toggle="yes">LigPrep</italic> in the Schrodinger suite was used to process target compounds. OPLS_2005 force field was selected, and the pH was set to 7.0&#x000a0;&#x000b1;&#x000a0;2.0. Other parameters were kept as default. Subsequently, human HDAC1 (PDB ID: 5ICN) or HDAC2 (PDB ID: 4LXZ) were obtained from RCSB PDB (<ext-link xlink:href="https://www.rcsb.org" ext-link-type="uri">https://www.rcsb.org</ext-link>), and the protein preparation wizard was used to perform pretreatments such as removing waters, hydrogenating, charging, and adjusting the protonation state of histidine residues near zinc ions [<xref rid="mco270500-bib-0053" ref-type="bibr">53</xref>]. Next, the ligand in the processed protein was chosen to generate a docking grid with 20&#x000a0;&#x000c5;, and the remaining parameters were kept as default. The Glide module in the Schrodinger suite was used to dock the processed ligands and the docking grid. The docking accuracy was XP mode, and the remaining options remain the default [<xref rid="mco270500-bib-0054" ref-type="bibr">54</xref>]. Fragment&#x02010;centric topographical mapping (FCTM) of protein&#x02010;ligand binding area was performed using <italic toggle="yes">AlphaSpace</italic> [<xref rid="mco270500-bib-0028" ref-type="bibr">28</xref>] and the figures were illustrated by UCSF Chimera [<xref rid="mco270500-bib-0055" ref-type="bibr">55</xref>].</p></sec><sec id="mco270500-sec-0240"><label>4.9</label><title>Immunoblotting Assay</title><p>Anti&#x02010;H3 (#13998), anticleaved Caspase&#x02010;3 (#9661) and anti&#x02010;PARP (#9542) antibody was purchased from Cell Signal Technology (CST). Anti&#x02010;Caspase&#x02010;3 (T40044) was brought from Abmart. Antitubulin antibody (ab179484) was obtained from Abcam PLC. Anti&#x02010;Bcl&#x02010;2 (F0125) and anti&#x02010;Bax (F0037) antibody were purchased from Selleck Chemicals. Anti&#x02010;GAPDH antibody (AF1186) was obtained from Beyotime Inc. The protocol of Western blotting was the same as our previous works [<xref rid="mco270500-bib-0050" ref-type="bibr">50</xref>]. In brief, 2.5&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> MDA&#x02010;MB&#x02010;231 cells were treated with different drugs or DMSO (equal volume to experimental groups) for 24&#x000a0;h and lysed with modified RIPA buffer. The cell lysates were added to loading buffer (Beyotime #P0015L) and heated in boiling water for 5 mins and then, together with biomarker (Epizymebiotech; 15&#x02013;250&#x000a0;kDa), were electrophoresed in SDS&#x02010;PAGE gels under 80&#x000a0;V voltage until the biomarker reached the end of gels. Next, SDS&#x02010;PAGE gels and PVDF membrane were clipped together to perform transmembrane procedure under 350&#x000a0;mA currency for 1 h. Then after incubation with 5% skim milk, TBST, primary antibody and secondary antibody, the PVDF membrane was treated with ECL chemiluminescence solution (Boster Biological Technology #AR1174) and imaged by the imager (Imager 680 Amersham Imager).</p></sec><sec id="mco270500-sec-0250"><label>4.10</label><title>Immunofluorescence Assay</title><p>Cells (10<sup>5</sup> cells per plate) were seeded in confocal dishes and incubated with drugs or DMSO (equal volume to experimental groups) for 24&#x000a0;h. The medium was removed, and cells were fixed with 4% polyoxymethylene solution for 30&#x000a0;min. The cells were treated with 0.2% Triton X&#x02010;100 for 10&#x000a0;min and 1% BSA for 1&#x000a0;h at room temperature. After that, cells were washed twice with TBST and incubated with anti&#x02010;H3 antibody (Cell Signal Technology; #13998) at 4&#x000b0;C overnight. When incubation finished, cells were washed five times with TBST and Cy3&#x02010;labeled goat anti&#x02010;rabbit IgG (Beyotime; #A0516) and DAPI solution (Solarbio) were added. After 1&#x000a0;h incubation and washing five times with TBST, cells were captured with Leica TCS SP8 super&#x02010;resolution laser scanning confocal microscope. The colocalization of ac&#x02010;H3 and DAPI was analyzed with ImageJ.</p></sec><sec id="mco270500-sec-0260"><label>4.11</label><title>shRNA Transfection and Flow Cytometry</title><p>MDA&#x02010;MB&#x02010;231 cells in logarithmic growth phase were inoculated into six&#x02010;well plates with a cell density of 3&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup> cells per well. After incubated at 37&#x000b0;C for 24 h, the original medium was abandoned and 900&#x000a0;&#x000b5;L complete medium was added, in which HitransG P infection solution was added. The virus dosage was calculated according to the formula and added to the cell. Virus volume&#x000a0;=&#x000a0;cell number&#x000a0;&#x000d7;&#x000a0;MOI value/virus titer. After incubated in the incubator at 37&#x000b0;C for 16&#x000a0;h, replace fresh complete medium. After that, the medium changed every 24&#x000a0;h. 48&#x000a0;h after infection, the cells were treated with or without compound at a concentration of 1&#x000a0;&#x000b5;M. After 48&#x000a0;h of culture, the fluorescence expression was observed under microscope, and the silencing effect of shHDAC1 was detected by Western Blot. The antibodies HDAC1 (Abmart; #T55154) and GAPDH (Beyotime; #AF2819) were used. The HDAC1&#x02010;siRNA lentivirus (shHDAC1) and negative control lentivirus (shCtrl) were obtained from Shanghai GeneChem Co., Ltd. (Shanghai, China).</p><p>Next, cells were digested into single&#x02010;cell suspension with trypsin, collected in a flow tube and washed with precooled 1&#x000a0;&#x000d7;&#x000a0;PBS. Mouse serum was added to cells for 30&#x000a0;min at room temperature to block cells. Then the cells were incubated with anti&#x02010;human&#x02010;PD&#x02010;L1 (BioLegend; #329732) at 4&#x000b0;C for 1&#x000a0;h, and flow cytometry was performed with FACS Celesta (BD Biosciences, USA). Use FlowJo software to analyze the data.</p></sec><sec id="mco270500-sec-0270"><label>4.12</label><title>In Vitro Metabolic Assay</title><p>Compounds were prepared in a working solution of 2&#x000a0;mg/mL with methanol. Mouse liver microsomes (4&#x000a0;mg/mL; Research Institute for Liver Disease (Shanghai) Co., Ltd) were mixed with NADPH (the final concentration is 4&#x000a0;mM), MgCl<sub>2</sub> (the final concentration is 6&#x000a0;mM), and shaken at 37&#x000b0;C for 5&#x000a0;min. Then, compound solutions were added to the system and incubated for 0, 10, 20, 30, 60, 90, and 120&#x000a0;min at 37&#x000b0;C under shaking conditions. The mixture was quenched with cold acetonitrile and analyzed with a Shimadzu LC&#x02010;20AT system and a C18&#x02010;silica column (Thermo; 4.6&#x000a0;&#x000d7;&#x000a0;250&#x000a0;mm, 5&#x000a0;&#x000b5;m).</p></sec><sec id="mco270500-sec-0280"><label>4.13</label><title>In Vivo Pharmacokinetic Study</title><p>The compound was prepared in a 1&#x000a0;mg/mL working solution using DMSO/solutol/saline. SD rats (6&#x02013;8 weeks old, 180&#x02013;200&#x000a0;g, male) were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China) and fed in accordance with the guidelines for the care and use of laboratory animals of the ethical committee of Shandong University. The doses were 2.5&#x000a0;mg/kg (i.v.) and 10&#x000a0;mg/kg (i.g.), with three animals per treatment group. Blood samples were collected from the jugular vein at different time points using heparin sodium anticoagulation tubes. After anesthetizing rats with ether, blood samples were placed in an ice water mixture for 15&#x000a0;min, then centrifuged at 3000&#x000d7;<italic toggle="yes">g</italic>&#x000a0;for 3&#x000a0;min to separate the plasma, and stored at &#x02212;20&#x000b0;C. The LC&#x02013;MS/MS was used to detect the concentration of the analyte at each time point, and the pharmacokinetic parameters were calculated using WinNolin8.2 software.</p></sec><sec id="mco270500-sec-0290"><label>4.14</label><title>MDA&#x02010;MB&#x02010;231 Xenograft Model</title><p>BALB/c&#x02010;nu mice were obtained from Pengyue Co. Ltd. (Jinan, China) and were fed in laminar flow cabinets under specific pathogen&#x02010;free (SPF) conditions. With the approval of ethics committee of Shandong University, the animal experiments were conducted. To establish the MDA&#x02010;MB&#x02010;231 xenograft model, BALB/c&#x02010;nu mice (3&#x02013;4 weeks old and 15&#x02013;18&#x000a0;g body weight, male) were selected and injected subcutaneously into the armpits with 1.2&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup> MDA&#x02010;MB&#x02010;231 cells. By the time tumors reached the volume of 100&#x000a0;mm<sup>3</sup>, <bold>SDFZ&#x02010;8</bold> or <bold>SAHA</bold> treatment (compounds dissolved in normal saline containing 10% DMSO and 20% Cremophor EL, 60&#x000a0;mg/kg, qd, i.g.,) was started, with five animals per treatment group. Body weight and tumor size were measured every 3 days during the 22&#x02010;day treatment.</p></sec><sec id="mco270500-sec-0300"><label>4.15</label><title>MC38 Syngeneic Model</title><p>C57BL/6J mice were obtained from HFK Bioscience (Beijing, China) and fed in laminar flow cabinets under SPF conditions. With the approval of the ethics committee of Shandong University, the animal experiments were conducted. To establish the MC38 syngeneic model, C57BL/6J mice (6&#x02013;7 weeks old and 19&#x02013;24&#x000a0;g body weight, male) were selected and injected subcutaneously into the armpits with 1.0&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> MC38 cells. By the time tumors reached certain volumes, <bold>SDFZ&#x02010;8</bold> treatment (<bold>SDFZ&#x02010;8</bold> in PBS solution containing 5% DMSO, 60&#x000a0;mg/kg, qd, i.g.) was started, with five animals per treatment group. Body weight and tumor size were measured every day during the 14&#x02010;day treatment.</p><p>After 14 days, the tumors and spleens were split, and cells were isolated to analyze the change in cancer immunity. For TILs, the tumors were incubated with the tumor digestion fluid (collagenase and hyaluronic acid included) and then filtered with a 200&#x02010;gauge mesh and centrifuged (100&#x000d7;<italic toggle="yes">g</italic>, 1&#x000a0;min). The supernatant was centrifuged (400&#x000d7;<italic toggle="yes">g</italic>, 5&#x000a0;min) and precipitated cells were purified by 40% percoll solution followed by RBC lysis and washing. For splenocytes, the spleen was passed through a 200&#x02010;gauge mesh, and splenocytes were collected after RBC lysis and washing.</p><p>The prepared cell suspensions were incubated with rat serum at room temperature for 30&#x000a0;min to block the FC&#x02010;receptor and incubated with fluorescent antibodies at 4&#x000b0;C for 1&#x000a0;h. For Foxp3 staining, Foxp3/Transcription Factor Staining Buffer Set (eBioscience; #00&#x02010;5523&#x02010;00) was used. For intracellular cytokines staining, cells were pre&#x02010;stimulated with 1 &#x000b5;g/mL ionomycin (Beyotime; #S1672), 50&#x000a0;ng/mL PMA (Sigma; #P1585) and Brefeldin A (BioLegend; #420601) for 4&#x000a0;h. The antibodies used in this work were listed in <bold>Table</bold>
<xref rid="mco270500-supinfo-0001" ref-type="">
<bold>S3</bold>
</xref>. Flow cytometry was conducted with FACS Celesta (BD Biosciences, USA) and analyzed with FlowJo software.</p></sec><sec id="mco270500-sec-0310"><label>4.16</label><title>B16F10 syngeneic Model</title><p>With the approval of the ethics committee of Shandong University, C57BL/6J mice were purchased from Charles River and fed in SPF conditions at the Model Animal Research Centre of Shandong University. To establish the B16F10 syngeneic model, cells in logarithmic growth phase were trypsinized with 0.25% trypsin, resuspended in sterile PBS, and adjusted to 1&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> cells/100&#x000a0;&#x000b5;L. The cell suspension (100&#x000a0;&#x000b5;L) was subcutaneously injected into the left axilla. When tumors reached to certain volume, mice were randomized (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;5/group) and treated with Chidamide, LBH&#x02010;589, or SDFZ&#x02010;8 by oral gavage and intraperitoneal injection of anti&#x02010;PD&#x02010;L1. Tumor growth curves were plotted over a 7&#x02010;day treatment cycle. All procedures complied with AAALAC International guidelines for humane endpoint criteria.</p></sec><sec id="mco270500-sec-0320"><label>4.17</label><title>H&#x00026;E Staining</title><p>The tissue of organs was fixed and embedded in paraffin and cut into 5&#x000a0;&#x000b5;m sections. Tissue sections were stained with H&#x00026;E for histopathological evaluation. Briefly, the discs were immersed in two variations of xylene and a range of reduced alcohol concentrations and finally immersed in single&#x02010;distilled water. The next step was staining with Harris's hematoxylin reagent for 5&#x000a0;min, decolorizing with 1% Hydrochloric acid ethanol for 30&#x000a0;s and rinsing with tap water. The sections were then stained with eosin for 5&#x000a0;min and washed off with tap water. After dehydration with alcohol and xylene, the sections were sealed with neutral resin and the histopathologic change was observed with microscopy.</p></sec><sec id="mco270500-sec-0330"><label>4.18</label><title>Statistical Analysis</title><p>Groups were compared using unpaired two&#x02010;tailed <italic toggle="yes">t</italic>&#x02010;tests and two&#x02010;way analysis of variance was performed when comparing multiple samples. A <italic toggle="yes">p</italic> value less than 0.05 was considered statistically significant (*compared with vehicle, *<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, **<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, ***<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, ****<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). All statistical analysis was conducted using GraphPad Prism version 6 software (San Diego, CA).</p></sec></sec><sec id="mco270500-sec-0340"><title>Author Contributions</title><p>
<bold>Yi Zhou</bold>: writing&#x02014;review and editing, methodology, investigation, data curation, and funding acquisition. <bold>Jintong Du</bold>: writing&#x02014;review and editing, methodology, investigation, and data curation. <bold>Xue Li</bold>: writing&#x02014;review and editing, methodology, investigation, and data curation. <bold>Huajun Zhao</bold>: writing&#x02014;review and editing, methodology, and investigation. <bold>Junxin Xue</bold>: writing&#x02014;review and editing and investigation. <bold>Yuchen Liu</bold>: writing&#x02014;review and editing and investigation. <bold>Xinying Yang</bold>: writing&#x02014;review and editing, data curation, and investigation. <bold>Jinming Yu</bold>: writing&#x02014;review and editing and conceptualization. <bold>Xuben Hou</bold>: writing&#x02014;original draft, conceptualization, project administration, and funding acquisition. <bold>Hao Fang</bold>: writing&#x02014;review and editing, investigation, writing&#x02014;review and editing, project administration, funding acquisition, and conceptualization. All authors have read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="mco270500-sec-0360"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="mco270500-sec-0370"><title>Ethics Statement</title><p>All experiments were approved by the Institutional Animal Care and Use Committee of Shandong University and carried out following the Guide for the Care and Use of Laboratory Animals (Approval No. 240138). All tumor dimensions in our mouse xenograft models adhered to the specified limits.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="mco270500-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="mco270500-supitem-0001" position="float" content-type="local-data"><caption><p>Figure S1: Inhibition curves used to determine the IC<sub>50</sub> values of target compounds against HeLa unclear extract.</p><p>Figure S2: Inhibition curves used to determine the IC<sub>50</sub> values of SDFZ&#x02010;8 and SAHA against different HDACs.</p><p>Figure S3: Co&#x02010;localization analysis of ac&#x02010;H3 immunofluorescence and cell nuclear in 1&#x000a0;&#x000b5;M SDFZ&#x02010;8 treated MDA&#x02010;MB&#x02010;231 cells for 24 h: (A) Immunofluorescence of the ac&#x02010;H3, (B) Imaging of nuclear target dye DAPI, (C) The distribution of fluorescence intensity on the line, (D) Dot&#x02010;plot of the two channels.</p><p>Figure S4: Inhibition curves used to determine the IC50 values of SDFZ&#x02010;8 and SAHA against different cancer cells for 48 h treatment.</p><p>Figure S5: Metabolic stability of SDFZ&#x02010;8 in mouse liver microsomes: <sup>a</sup>R<sup>2</sup> is the coefficient of determination of the nonlinear regression of the data: <sup>b</sup>CLint (mic) is the intrinsic clearance in the unit of&#x000a0;&#x000b5;L/min/mg.</p><p>Figure S6: Change of body weight of nude mice after administration of SDFZ&#x02010;8 and SAHA in the MDA&#x02010;MB&#x02010;231 xenograft model (A), MC38 syngeneic model (B) and the B16F10 melanoma model (C).</p><p>Figure S7: Hematoxylin&#x02010;eosin staining results of the lung, kidney, liver, heart, spleen and tumor of each animal group in the MC38 syngeneic model.</p><p>Figure S8: Impacts of SAHA and SDFZ&#x02010;8 on immune cells in the spleen.</p><p>Figure S9: <sup>1</sup>H&#x02010;NMR spectrum of SDFZ&#x02010;8.</p><p>Figure S10: <sup>13</sup>C&#x02010;NMR spectrum of SDFZ&#x02010;8.</p><p>Figure S11: HRMS spectrum of SDFZ&#x02010;8.</p><p>Table S1: Antiproliferation activity of selected compounds<sup>a</sup>.</p><p>Table S2: Summary of in vivo anti&#x02010;tumor activities.</p><p>Table S3: Information for the antibodies used in tumor immunity study.</p></caption><media xlink:href="MCO2-6-e70500-s001.pdf"/></supplementary-material></sec></body><back><ack id="mco270500-sec-0350"><title>Acknowledgments</title><p>This work was supported by the National Natural Science Foundation of China (81874288, 82003590, 22377068, 82204198 and 92053105), the Taishan Scholars Program of Shandong Province (tstp20230606), and the Shandong Provincial Youth Innovation Team Development Program (2023KJ026). We genuinely thank the Advanced Medical Research Institute, Shandong University, for their help in the experiments.</p></ack><sec sec-type="data-availability" id="mco270500-sec-0390"><title>Data Availability Statement</title><p>Data will be made available on request.</p></sec><ref-list id="mco270500-bibl-0001"><title>References</title><ref id="mco270500-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mco270500-cite-0001">
<string-name>
<given-names>M. A.</given-names>
<surname>Dawson</surname>
</string-name> and <string-name>
<given-names>T.</given-names>
<surname>Kouzarides</surname>
</string-name>, &#x0201c;<article-title>Cancer Epigenetics: From Mechanism to Therapy</article-title>,&#x0201d; <source>Cell</source>
<volume>150</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>12</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">22770212</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mco270500-cite-0002">
<string-name>
<given-names>X. J.</given-names>
<surname>Yang</surname>
</string-name> and <string-name>
<given-names>E.</given-names>
<surname>Seto</surname>
</string-name>, &#x0201c;<article-title>HATs and HDACs: From Structure, Function and Regulation to Novel Strategies for Therapy and Prevention</article-title>,&#x0201d; <source>Oncogene</source>
<volume>26</volume>, no. <issue>37</issue> (<year>2007</year>): <fpage>5310</fpage>&#x02013;<lpage>5318</lpage>.<pub-id pub-id-type="pmid">17694074</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mco270500-cite-0003">
<string-name>
<given-names>P.</given-names>
<surname>Bertrand</surname>
</string-name>, &#x0201c;<article-title>Inside HDAC With HDAC Inhibitors</article-title>,&#x0201d; <source>European Journal of Medicinal Chemistry</source>
<volume>45</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>2095</fpage>&#x02013;<lpage>2116</lpage>.<pub-id pub-id-type="pmid">20223566</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mco270500-cite-0004">
<string-name>
<given-names>M.</given-names>
<surname>New</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Olzscha</surname>
</string-name>, and <string-name>
<given-names>N. B.</given-names>
<surname>La Thangue</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitor&#x02010;based Therapies: Can We Interpret the Code?</article-title>,&#x0201d; <source>Molecular Oncology</source>
<volume>6</volume>, no. <issue>6</issue> (<year>2012</year>): <fpage>637</fpage>&#x02013;<lpage>656</lpage>.<pub-id pub-id-type="pmid">23141799</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mco270500-cite-0005">
<string-name>
<given-names>S.</given-names>
<surname>Minucci</surname>
</string-name> and <string-name>
<given-names>P. G.</given-names>
<surname>Pelicci</surname>
</string-name>, &#x0201c;<article-title>Histone Deacetylase Inhibitors and the Promise of Epigenetic (and more) Treatments for Cancer</article-title>,&#x0201d; <source>Nature Reviews Cancer</source>
<volume>6</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>38</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">16397526</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mco270500-cite-0006">
<string-name>
<given-names>J.</given-names>
<surname>Xue</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Hou</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Fang</surname>
</string-name>, &#x0201c;<article-title>Structure, Functions, and Recent Advances in the Development of SIRT2 Inhibitors</article-title>,&#x0201d; <source>Pharmaceutical Science Advances</source>
<volume>1</volume>, no. <issue>2</issue> (<year>2023</year>): <elocation-id>100010</elocation-id>.</mixed-citation></ref><ref id="mco270500-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mco270500-cite-0007">
<string-name>
<given-names>K. R.</given-names>
<surname>Stengel</surname>
</string-name> and <string-name>
<given-names>S. W.</given-names>
<surname>Hiebert</surname>
</string-name>, &#x0201c;<article-title>Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy</article-title>,&#x0201d; <source>Antioxid Redox Signaling</source>
<volume>23</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>51</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="mco270500-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mco270500-cite-0008">
<string-name>
<given-names>O.</given-names>
<surname>Witt</surname>
</string-name>, <string-name>
<given-names>H. E.</given-names>
<surname>Deubzer</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Milde</surname>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Oehme</surname>
</string-name>, &#x0201c;<article-title>HDAC family: What Are the Cancer Relevant Targets?</article-title>,&#x0201d; <source>Cancer Letter</source>
<volume>277</volume>, no. <issue>1</issue> (<year>2009</year>): <fpage>8</fpage>&#x02013;<lpage>21</lpage>.</mixed-citation></ref><ref id="mco270500-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mco270500-cite-0009">
<string-name>
<given-names>M.</given-names>
<surname>Vogelauer</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Rubbi</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Lucas</surname>
</string-name>, <string-name>
<given-names>B. J.</given-names>
<surname>Brewer</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Grunstein</surname>
</string-name>, &#x0201c;<article-title>Histone Acetylation Regulates the Time of Replication Origin Firing</article-title>,&#x0201d; <source>Molecular Cell</source>
<volume>10</volume>, no. <issue>5</issue> (<year>2002</year>): <fpage>1223</fpage>&#x02013;<lpage>1233</lpage>.<pub-id pub-id-type="pmid">12453428</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mco270500-cite-0010">
<string-name>
<given-names>S.</given-names>
<surname>Mithraprabhu</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kalff</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Chow</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Khong</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Spencer</surname>
</string-name>, &#x0201c;<article-title>Dysregulated Class I Histone Deacetylases Are Indicators of Poor Prognosis in Multiple Myeloma</article-title>,&#x0201d; <source>Epigenetics&#x02010;US</source>
<volume>9</volume>, no. <issue>11</issue> (<year>2014</year>): <fpage>1511</fpage>&#x02013;<lpage>1520</lpage>.</mixed-citation></ref><ref id="mco270500-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mco270500-cite-0011">
<string-name>
<given-names>E. M.</given-names>
<surname>Conway</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Collen</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Carmeliet</surname>
</string-name>, &#x0201c;<article-title>Molecular Mechanisms of Blood Vessel Growth</article-title>,&#x0201d; <source>Cardiovascular Research</source>
<volume>49</volume>, no. <issue>3</issue> (<year>2001</year>): <fpage>507</fpage>&#x02013;<lpage>521</lpage>.<pub-id pub-id-type="pmid">11166264</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="mco270500-cite-0012">
<string-name>
<given-names>D.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Kong</surname>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>Sang</surname>
</string-name>, &#x0201c;<article-title>Effects of Histone Deacetylase Inhibitors on HIF&#x02010;1</article-title>,&#x0201d; <source>Cell Cycle</source>
<volume>5</volume>, no. <issue>21</issue> (<year>2006</year>): <fpage>2430</fpage>&#x02013;<lpage>2435</lpage>.<pub-id pub-id-type="pmid">17102633</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="mco270500-cite-0013">
<string-name>
<given-names>M. S.</given-names>
<surname>Roca</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Di Gennaro</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Budillon</surname>
</string-name>, &#x0201c;<article-title>Implication for Cancer Stem Cells in Solid Cancer Chemo&#x02010;Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors</article-title>,&#x0201d; <source>Journal of Clinical Medicine</source>
<volume>8</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>912</fpage>.<pub-id pub-id-type="pmid">31247937</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="mco270500-cite-0014">
<string-name>
<given-names>L.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ma</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Zhang</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitors: A New Radiosensitizer for Non&#x02010;small&#x02010;cell Lung Cancer</article-title>,&#x0201d; <source>Tumori Journal</source>
<volume>101</volume>, no. <issue>3</issue> (<year>2015</year>): <fpage>257</fpage>&#x02013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">25953446</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mco270500-cite-0015">
<string-name>
<given-names>S. J.</given-names>
<surname>Hogg</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Beavis</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Dawson</surname>
</string-name>, and <string-name>
<given-names>R. W.</given-names>
<surname>Johnstone</surname>
</string-name>, &#x0201c;<article-title>Targeting the Epigenetic Regulation of Antitumour Immunity</article-title>,&#x0201d; <source>Nature Reviews Drug Discovery</source>
<volume>19</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>776</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">32929243</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mco270500-cite-0016">
<string-name>
<given-names>S. Y.</given-names>
<surname>Deng</surname>
</string-name>, <string-name>
<given-names>Q. W.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Peng</surname>
</string-name>, and <string-name>
<given-names>C. X.</given-names>
<surname>Huang</surname>
</string-name>, &#x0201c;<article-title>HDAC3 Inhibition Upregulates PD&#x02010;L1 Expression in B&#x02010;Cell Lymphomas and Augments the Efficacy of Anti&#x02010;PD&#x02010;L1 Therapy</article-title>,&#x0201d; <source>Molecular Cancer Therapeutics</source>
<volume>18</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>900</fpage>&#x02013;<lpage>908</lpage>.<pub-id pub-id-type="pmid">30824609</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mco270500-cite-0017">
<string-name>
<given-names>Y.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>N. T.</given-names>
<surname>Nihira</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Bu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Acetylation&#x02010;dependent Regulation of PD&#x02010;L1 Nuclear Translocation Dictates the Efficacy of anti&#x02010;PD&#x02010;1 Immunotherapy</article-title>,&#x0201d; <source>Nature Cell Biology</source>
<volume>22</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>1064</fpage>.<pub-id pub-id-type="pmid">32839551</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mco270500-cite-0018">
<string-name>
<given-names>N. J.</given-names>
<surname>Porter</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Osko</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Diedrich</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Histone Deacetylase 6&#x02010;Selective Inhibitors and the Influence of Capping Groups on Hydroxamate&#x02010;Zinc Denticity</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>61</volume>, no. <issue>17</issue> (<year>2018</year>): <fpage>8054</fpage>&#x02013;<lpage>8060</lpage>.<pub-id pub-id-type="pmid">30118224</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="mco270500-cite-0019">
<string-name>
<given-names>N. J.</given-names>
<surname>Porter</surname>
</string-name> and <string-name>
<given-names>D. W.</given-names>
<surname>Christianson</surname>
</string-name>, &#x0201c;<article-title>Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8</article-title>,&#x0201d; <source>ACS Chemical Biology</source>
<volume>12</volume>, no. <issue>9</issue> (<year>2017</year>): <fpage>2281</fpage>&#x02013;<lpage>2286</lpage>.<pub-id pub-id-type="pmid">28846375</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mco270500-cite-0020">
<string-name>
<given-names>K.</given-names>
<surname>Yue</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Jia</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>First&#x02010;in&#x02010;Class Hydrazide&#x02010;Based HDAC6 Selective Inhibitor With Potent Oral Anti&#x02010;Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>65</volume>, no. <issue>18</issue> (<year>2022</year>): <fpage>12140</fpage>&#x02013;<lpage>12162</lpage>.<pub-id pub-id-type="pmid">36073117</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mco270500-cite-0021">
<string-name>
<given-names>T.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Elhassan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Targeting Histone Deacetylases for Cancer Therapy: Trends and Challenges</article-title>,&#x0201d; <source>Acta Pharmaceutica Sinica B</source>
<volume>13</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>2425</fpage>&#x02013;<lpage>2463</lpage>.<pub-id pub-id-type="pmid">37425042</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mco270500-cite-0022">
<string-name>
<given-names>M. Q.</given-names>
<surname>Shi</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Fu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Advances in Targeting Histone Deacetylase for Treatment of Solid Tumors</article-title>,&#x0201d; <source>Journal of Hematology &#x00026; Oncology</source>
<volume>17</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>37</fpage>.<pub-id pub-id-type="pmid">38822399</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="mco270500-cite-0023">
<string-name>
<given-names>B.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Pan</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Xiao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>HDAC&#x02010;targeting Epigenetic Modulators for Cancer Immunotherapy</article-title>,&#x0201d; <source>European Journal of Medicinal Chemistry</source>
<volume>265</volume> (<year>2024</year>): <elocation-id>116129</elocation-id>.<pub-id pub-id-type="pmid">38211468</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="mco270500-cite-0024">
<string-name>
<given-names>X. B.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Rooklin</surname>
</string-name>, <string-name>
<given-names>D. X.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Computational Strategy for Bound State Structure Prediction in Structure&#x02010;Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors</article-title>,&#x0201d; <source>Journal of Chemical Information and Modeling</source>
<volume>58</volume>, no. <issue>11</issue> (<year>2018</year>): <fpage>2331</fpage>&#x02013;<lpage>2342</lpage>.<pub-id pub-id-type="pmid">30299094</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="mco270500-cite-0025">
<string-name>
<given-names>R.</given-names>
<surname>Musiol</surname>
</string-name>, &#x0201c;<article-title>An Overview of Quinoline as a Privileged Scaffold in Cancer Drug Discovery</article-title>,&#x0201d; <source>Expert Opinion on Drug Discovery</source>
<volume>12</volume>, no. <issue>6</issue> (<year>2017</year>): <fpage>583</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">28399679</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="mco270500-cite-0026">
<string-name>
<given-names>C.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Design, Synthesis and Biological Evaluation of Quinoline Derivatives as HDAC Class I Inhibitors</article-title>,&#x0201d; <source>European Journal of Medicinal Chemistry</source>
<volume>133</volume> (<year>2017</year>): <fpage>11</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">28371677</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="mco270500-cite-0027">
<string-name>
<given-names>L.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>X. B.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>H. S.</given-names>
<surname>Fu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Design, Synthesis and Preliminary Bioactivity Evaluations of Substituted Quinoline Hydroxamic Acid Derivatives as Novel Histone Deacetylase (HDAC) Inhibitors</article-title>,&#x0201d; <source>Bioorganic &#x00026; Medicinal Chemistry</source>
<volume>23</volume>, no. <issue>15</issue> (<year>2015</year>): <fpage>4364</fpage>&#x02013;<lpage>4374</lpage>.<pub-id pub-id-type="pmid">26149591</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="mco270500-cite-0028">
<string-name>
<given-names>D.</given-names>
<surname>Rooklin</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Katigbak</surname>
</string-name>, <string-name>
<given-names>P. S.</given-names>
<surname>Arora</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, &#x0201c;<article-title>AlphaSpace: Fragment&#x02010;Centric Topographical Mapping To Target Protein&#x02010;Protein Interaction Interfaces</article-title>,&#x0201d; <source>Journal of Chemical Information and Modeling</source>
<volume>55</volume>, no. <issue>8</issue> (<year>2015</year>): <fpage>1585</fpage>&#x02013;<lpage>1599</lpage>.<pub-id pub-id-type="pmid">26225450</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="mco270500-cite-0029">
<string-name>
<given-names>H.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Qu</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Jin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer</article-title>,&#x0201d; <source>Cancer Cell</source>
<volume>30</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>459</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">27622335</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="mco270500-cite-0030">
<string-name>
<given-names>E. E.</given-names>
<surname>Hull</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Montgomery</surname>
</string-name>, and <string-name>
<given-names>K. J.</given-names>
<surname>Leyva</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases</article-title>,&#x0201d; <source>Biomed Research International</source>
<volume>2016</volume> (<year>2016</year>): <elocation-id>8797206</elocation-id>.<pub-id pub-id-type="pmid">27556043</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="mco270500-cite-0031">
<string-name>
<given-names>M.</given-names>
<surname>Conte</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>De Palma</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Altucci</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitors as Epigenetic Regulators for Cancer Immunotherapy</article-title>,&#x0201d; <source>International Journal of Biological Macromolecules</source>
<volume>98</volume> (<year>2018</year>): <fpage>65</fpage>&#x02013;<lpage>74</lpage>.</mixed-citation></ref><ref id="mco270500-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="mco270500-cite-0032">
<string-name>
<given-names>C.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Zhao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Discovery of DNA&#x02010;Targeting HDAC Inhibitors With Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>65</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>3667</fpage>&#x02013;<lpage>3683</lpage>.<pub-id pub-id-type="pmid">35152694</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="mco270500-cite-0033">
<string-name>
<given-names>W.</given-names>
<surname>Yan</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ling</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Structure&#x02010;Based Design of Dual&#x02010;Acting Compounds Targeting Adenosine A(2A) Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>64</volume>, no. <issue>22</issue> (<year>2021</year>): <fpage>16573</fpage>&#x02013;<lpage>16597</lpage>.<pub-id pub-id-type="pmid">34783558</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="mco270500-cite-0034">
<string-name>
<given-names>X.</given-names>
<surname>Peng</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Chen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors With Enhanced Antitumor Immunity of Anti&#x02010;PD&#x02010;L1 Immunotherapy in Melanoma</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>65</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>2434</fpage>&#x02013;<lpage>2457</lpage>.<pub-id pub-id-type="pmid">35043615</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="mco270500-cite-0035">
<string-name>
<given-names>D. M.</given-names>
<surname>Woods</surname>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Sodre</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Villagra</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sarnaik</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Sotomayor</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Weber</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibition Upregulates PD&#x02010;1 Ligands in Melanoma and Augments Immunotherapy With PD&#x02010;1 Blockade</article-title>,&#x0201d; <source>Cancer Immunology Research</source>
<volume>3</volume>, no. <issue>12</issue> (<year>2015</year>): <fpage>1375</fpage>&#x02013;<lpage>1385</lpage>.<pub-id pub-id-type="pmid">26297712</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mco270500-cite-0036">
<string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Song</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Du</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gong</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Chang</surname>
</string-name>, and <string-name>
<given-names>Z.</given-names>
<surname>Zou</surname>
</string-name>, &#x0201c;<article-title>Tumor&#x02010;associated Macrophages: An Accomplice in Solid Tumor Progression</article-title>,&#x0201d; <source>Journal of Biomedical Science</source>
<volume>26</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>78</fpage>.<pub-id pub-id-type="pmid">31629410</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="mco270500-cite-0037">
<string-name>
<given-names>Q. J.</given-names>
<surname>Xue</surname>
</string-name>, <string-name>
<given-names>Y. C.</given-names>
<surname>Yan</surname>
</string-name>, <string-name>
<given-names>R. H.</given-names>
<surname>Zhang</surname>
</string-name>, and <string-name>
<given-names>H. B.</given-names>
<surname>Xiong</surname>
</string-name>, &#x0201c;<article-title>Regulation of iNOS on Immune Cells and Its Role in Diseases</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>19</volume>, no. <issue>12</issue> (<year>2018</year>): <fpage>3805</fpage>.<pub-id pub-id-type="pmid">30501075</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="mco270500-cite-0038">
<string-name>
<given-names>A.</given-names>
<surname>Nawaz</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Aminuddin</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kado</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CD206(+) M2&#x02010;Like Macrophages Regulate Systemic Glucose Metabolism by Inhibiting Proliferation of Adipocyte Progenitors</article-title>,&#x0201d; <source>Nature Communications</source> (<year>2017</year>): <fpage>8</fpage>.</mixed-citation></ref><ref id="mco270500-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="mco270500-cite-0039">
<string-name>
<given-names>X. L.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Su</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>HDAC Inhibition Potentiates Anti&#x02010;tumor Activity of Macrophages and Enhances Anti&#x02010;PD&#x02010;L1&#x02010;mediated Tumor Suppression</article-title>,&#x0201d; <source>Oncogene</source>
<volume>40</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>1836</fpage>&#x02013;<lpage>1850</lpage>.<pub-id pub-id-type="pmid">33564072</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="mco270500-cite-0040">
<string-name>
<given-names>K.</given-names>
<surname>Cao</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Histone Deacetylase Inhibitors Prevent Activation&#x02010;induced Cell Death and Promote Anti&#x02010;tumor Immunity</article-title>,&#x0201d; <source>Oncogene</source>
<volume>34</volume>, no. <issue>49</issue> (<year>2015</year>): <fpage>5960</fpage>&#x02013;<lpage>5970</lpage>.<pub-id pub-id-type="pmid">25745993</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="mco270500-cite-0041">
<string-name>
<given-names>X. G.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>B. C.</given-names>
<surname>Waschke</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Woolaver</surname>
</string-name>, <string-name>
<given-names>S. M. Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Z. G.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>J. H.</given-names>
<surname>Wang</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitors Overcome Immunotherapy Resistance in B&#x02010;cell Lymphoma</article-title>,&#x0201d; <source>Protein Cell</source>
<volume>11</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>472</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">32162275</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="mco270500-cite-0042">
<string-name>
<given-names>M.</given-names>
<surname>Conte</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>De Palma</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Altucci</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitors as Epigenetic Regulators for Cancer Immunotherapy</article-title>,&#x0201d; <source>International Journal of Biochemistry &#x00026; Cell Biology</source>
<volume>98</volume> (<year>2018</year>): <fpage>65</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">29535070</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="mco270500-cite-0043">
<string-name>
<given-names>R. P.</given-names>
<surname>Bissonnette</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Rolland</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Goodeneow</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Gillings</surname>
</string-name>, &#x0201c;<article-title>The HDAC Inhibitor HBI&#x02010;8000 Enhances Immunotherapy With either PD&#x02010;1 or PD&#x02010;L1 Blockade in the MC38 Model of Colon Cancer</article-title>,&#x0201d; <source>Cancer Immunology Research</source>
<volume>4</volume>, no. <issue>11</issue> (<year>2016</year>).</mixed-citation></ref><ref id="mco270500-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="mco270500-cite-0044">
<string-name>
<given-names>H.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>W. P.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>C. H.</given-names>
<surname>Yan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>HDAC Inhibitors Enhance T&#x02010;Cell Chemokine Expression and Augment Response to PD&#x02010;1 Immunotherapy in Lung Adenocarcinoma</article-title>,&#x0201d; <source>Clinical Cancer Research</source>
<volume>22</volume>, no. <issue>16</issue> (<year>2016</year>): <fpage>4119</fpage>&#x02013;<lpage>4132</lpage>.<pub-id pub-id-type="pmid">26964571</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="mco270500-cite-0045">
<string-name>
<given-names>M.</given-names>
<surname>Kroesen</surname>
</string-name>, <string-name>
<given-names>P. R.</given-names>
<surname>Gielen</surname>
</string-name>, <string-name>
<given-names>I. C.</given-names>
<surname>Brok</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Armandari</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Hoogerbrugge</surname>
</string-name>, and <string-name>
<given-names>G. J.</given-names>
<surname>Adema</surname>
</string-name>, &#x0201c;<article-title>HDAC Inhibitors and Immunotherapy; a Double Edged Sword?</article-title>,&#x0201d; <source>Oncotarget</source>
<volume>5</volume>, no. <issue>16</issue> (<year>2014</year>): <fpage>6558</fpage>&#x02013;<lpage>6572</lpage>.<pub-id pub-id-type="pmid">25115382</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="mco270500-cite-0046">
<string-name>
<given-names>X.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>Q.</given-names>
<surname>Zhou</surname>
</string-name>, &#x0201c;<article-title>Emerging Role of PD&#x02010;L1 Modification in Cancer Immunotherapy</article-title>,&#x0201d; <source>American Journal of Cancer Research</source>
<volume>11</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>3832</fpage>&#x02013;<lpage>3840</lpage>.<pub-id pub-id-type="pmid">34522452</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="mco270500-cite-0047">
<string-name>
<given-names>L.</given-names>
<surname>M</surname>
</string-name>, <string-name>
<given-names>P. V.</given-names>
<surname>P</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>T</surname>
</string-name>, &#x0201c;<article-title>Essential Role of HDAC6 in the Regulation of PD&#x02010;L1 in Melanoma</article-title>,&#x0201d; <source>Molecular Oncology</source>
<volume>10</volume>, no. <issue>5</issue> (<year>2016</year>): <fpage>735</fpage>&#x02013;<lpage>750</lpage>.<pub-id pub-id-type="pmid">26775640</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="mco270500-cite-0048">
<string-name>
<given-names>Z.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>PD&#x02010;L1 Combined With HDAC9 Is a Useful Prognostic Predictor in Hepatocellular Carcinoma</article-title>,&#x0201d; <source>Translational Cancer Research</source>
<volume>10</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>2305</fpage>&#x02013;<lpage>2317</lpage>.<pub-id pub-id-type="pmid">35116547</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="mco270500-cite-0049">
<string-name>
<given-names>Y. K.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Jin</surname>
</string-name>, and <string-name>
<given-names>H. X.</given-names>
<surname>Yu</surname>
</string-name>, &#x0201c;<article-title>HDAC5 modulates PD&#x02010;L1 Expression and Cancer Immunity via p65 Deacetylation in Pancreatic Cancer</article-title>,&#x0201d; <source>Theranostics</source>
<volume>12</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>2080</fpage>&#x02013;<lpage>2094</lpage>.<pub-id pub-id-type="pmid">35265200</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="mco270500-cite-0050">
<string-name>
<given-names>Y.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>X. T.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>J. X.</given-names>
<surname>Xue</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>63</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>4701</fpage>&#x02013;<lpage>4715</lpage>.<pub-id pub-id-type="pmid">32267687</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="mco270500-cite-0051">
<string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>R. S.</given-names>
<surname>Liu</surname>
</string-name>, and <string-name>
<given-names>X. Y.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>X. B.</given-names>
<surname>Hou</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Fang</surname>
</string-name>, &#x0201c;<article-title>Design, Synthesis and Biological Evaluation of Tyrosine Derivatives as Mcl&#x02010;1 Inhibitors</article-title>,&#x0201d; <source>European Journal of Medicinal Chemistry</source> (<year>2020</year>): <fpage>191</fpage>.</mixed-citation></ref><ref id="mco270500-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="mco270500-cite-0052">
<string-name>
<given-names>T.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Yang</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Fang</surname>
</string-name>, &#x0201c;<article-title>Design, Synthesis, and Biological Evaluation of 2,4&#x02010;Imidazolinedione Derivatives as HDAC6 Isoform&#x02010;Selective Inhibitors</article-title>,&#x0201d; <source>ACS Medicinal Chemistry Letter</source>
<volume>10</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>1122</fpage>&#x02013;<lpage>1127</lpage>.</mixed-citation></ref><ref id="mco270500-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="mco270500-cite-0053">
<string-name>
<given-names>R. B.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>N. J.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>Z. X.</given-names>
<surname>Cao</surname>
</string-name>, and <string-name>
<given-names>Y. K.</given-names>
<surname>Zhang</surname>
</string-name>, &#x0201c;<article-title>A Proton&#x02010;Shuttle Reaction Mechanism for Histone Deacetylase 8 and the Catalytic Role of Metal Ions</article-title>,&#x0201d; <source>Journal of the American Chemical Society</source>
<volume>132</volume>, no. <issue>27</issue> (<year>2010</year>): <fpage>9471</fpage>&#x02013;<lpage>9479</lpage>.<pub-id pub-id-type="pmid">20568751</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="mco270500-cite-0054">
<string-name>
<given-names>R. A.</given-names>
<surname>Friesner</surname>
</string-name>, <string-name>
<given-names>R. B.</given-names>
<surname>Murphy</surname>
</string-name>, <string-name>
<given-names>M. P.</given-names>
<surname>Repasky</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein&#x02010;ligand Complexes</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>49</volume>, no. <issue>21</issue> (<year>2006</year>): <fpage>6177</fpage>&#x02013;<lpage>6196</lpage>.<pub-id pub-id-type="pmid">17034125</pub-id>
</mixed-citation></ref><ref id="mco270500-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="mco270500-cite-0055">
<string-name>
<given-names>E. F.</given-names>
<surname>Pettersen</surname>
</string-name>, <string-name>
<given-names>T. D.</given-names>
<surname>Goddard</surname>
</string-name>, <string-name>
<given-names>C. C.</given-names>
<surname>Huang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>UCSF Chimera&#x02013;a Visualization System for Exploratory Research and Analysis</article-title>,&#x0201d; <source>Journal of Computational Chemistry</source>
<volume>25</volume>, no. <issue>13</issue> (<year>2004</year>): <fpage>1605</fpage>&#x02013;<lpage>1612</lpage>.<pub-id pub-id-type="pmid">15264254</pub-id>
</mixed-citation></ref></ref-list></back></article>
